AMC Entertainment (AMC - Free Report) closed the most recent trading day at $1.87, moving -1.06% from the previous trading session. The stock's performance was behind the S&P 500's daily loss of 0.79%. Elsewhere, the Dow lost 0.26%, while the tech-heavy Nasdaq lost 1.55%.
Coming into today, shares of the movie theater operator had lost 19.23% in the past month. In that same time, the Consumer Discretionary sector gained 0.62%, while the S&P 500 gained 4.28%.
Analysts and investors alike will be keeping a close eye on the performance of AMC Entertainment in its upcoming earnings disclosure. Alongside, our most recent consensus estimate is anticipating revenue of $1.45 billion, indicating a 3.73% upward movement from the same quarter last year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.23 per share and revenue of $5.39 billion. These totals would mark changes of +76.04% and +11.1%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for AMC Entertainment. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 9.88% higher. As of now, AMC Entertainment holds a Zacks Rank of #2 (Buy).
The Leisure and Recreation Services industry is part of the Consumer Discretionary sector. Currently, this industry holds a Zacks Industry Rank of 104, positioning it in the top 43% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
TSMC (NYSE:TSM | TSM Price Prediction) started the week strong, reporting a 36% jump in quarterly sales, with June monthly revenue reaching roughly 442 billion Taiwan dollars, up 67.9% year over year. Even as the MSCI Asia Pacific index slid between 1.88% and 2.23%, TSMC shares climbed nearly 2%. Memory names moved the other direction, with SK Hynix falling 13% in the same session.
On Bloomberg “Daybreak Europe,” host Oliver Renick and Winnie Hsu framed the split as the story of the day. Hsu summarized the tone: “The bright spot is TSMC, stocks here up almost 2%. Taiwanese stocks were closed last week due to the typhoon, but trading is back online today, and we can expect June sales to be released later today.” Taiwanese markets had been shut the prior week due to a typhoon, with earnings expected later in the week.
AI Foundries Are Booming While Memory Stocks Get Crushed Memory chip stocks led Asian tech shares lower amid oversupply concerns and profit-taking, while foundries serving AI customers benefited from steady long-term demand. That distinction matters for U.S. investors because TSMC manufactures the flagship AI accelerators designed by NVIDIA and AMD, while both chipmakers rely on suppliers such as SK Hynix for HBM memory.
TSMC’s N3 production capacity is reportedly sold out, and the company is building three advanced packaging facilities in Phase II of Chiayi Science Park. Together, the facilities are expected to generate more than NT$300 billion in annual output and create 9,000 jobs.
NVIDIA Remains TSMC’s Most Important AI Customer NVIDIA (NASDAQ:NVDA) sits at the top of the TSMC customer stack. In its Q1 FY2027 report on May 20, 2026, NVIDIA posted non-GAAP EPS of $1.87 versus $1.77 expected, on revenue of $81.61B, up 85.2% year over year. CEO Jensen Huang has described the AI factory buildout as “the largest infrastructure expansion in human history.”
Wall Street continues to lean bullish. Morgan Stanley reiterated an Overweight rating with a $288 price target, citing four drivers: AI labs, hyperscalers, sovereign AI, and neocloud demand. Shares are up about 28.72% over the past year.
On the day of the TSMC news, NVIDIA traded down 1.99% to $206.77, tracking the broader Asia weakness rather than the foundry good news.
Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.
For readers looking to understand the broader capital cycle, our Free Report: 7 Stocks Powering the AI Boom explains how this infrastructure spending ripples through names beyond NVIDIA.
AMD Is Building Its Own Multi-Gigawatt AI Pipeline AMD (NASDAQ:AMD) is the other major TSMC AI customer. Q1 2026 non-GAAP EPS came in at $1.37 versus $1.29 expected, a 6.2% surprise, on revenue of $10.25B. Data Center revenue rose 57% year over year, with CEO Lisa Su citing accelerating AI infrastructure demand as the primary driver. Multi-gigawatt commitments from OpenAI and Meta on the MI450 series underpin the roadmap.
Shares are up 160.5% year to date and 286.99% over the past year. On the TSMC news day, AMD dropped 2.64% to $543.14. TradingKey attributed the pullback to sector-wide semiconductor volatility and anxieties about AI capex slowdowns. Analysts remain constructive, with 42 Buy ratings, 9 Holds, and an average target of $516.12.
TSMC’s Earnings On Thursday Could Reveal Whether AI Demand Is Still Supply-Constrained TSMC’s earnings report on Thursday could offer the clearest signal yet of whether AI chip demand continues to exceed available supply. TSMC’s reportedly sold-out N3 capacity points to continued strength in demand for advanced chips.
Investors should also watch whether the memory selloff begins to pressure HBM pricing. Any meaningful shift could affect the cost structure of NVIDIA’s Blackwell chips and AMD’s Instinct accelerators, making TSMC’s outlook an important read on the health of the broader AI supply chain.
Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.
Broadcom Inc. (AVGO - Free Report) closed at $384.05 in the latest trading session, marking a -3.98% move from the prior day. The stock's performance was behind the S&P 500's daily loss of 0.79%. Elsewhere, the Dow saw a downswing of 0.26%, while the tech-heavy Nasdaq depreciated by 1.55%.
Heading into today, shares of the chipmaker had gained 4.68% over the past month, outpacing the Computer and Technology sector's gain of 3.44% and the S&P 500's gain of 4.28%.
The upcoming earnings release of Broadcom Inc. will be of great interest to investors. The company's upcoming EPS is projected at $3.22, signifying a 90.53% increase compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $29.46 billion, indicating a 84.69% growth compared to the corresponding quarter of the prior year.
For the full year, the Zacks Consensus Estimates project earnings of $11.73 per share and a revenue of $105.63 billion, demonstrating changes of +71.99% and +65.34%, respectively, from the preceding year.
It is also important to note the recent changes to analyst estimates for Broadcom Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.01% higher. Broadcom Inc. is currently sporting a Zacks Rank of #3 (Hold).
Digging into valuation, Broadcom Inc. currently has a Forward P/E ratio of 34.1. This valuation marks a discount compared to its industry average Forward P/E of 49.67.
We can also see that AVGO currently has a PEG ratio of 0.61. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. AVGO's industry had an average PEG ratio of 1.86 as of yesterday's close.
The Electronics - Semiconductors industry is part of the Computer and Technology sector. At present, this industry carries a Zacks Industry Rank of 46, placing it within the top 19% of over 250 industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Jim Cramer used Monday’s Squawk on the Street to explain why SK Hynix’s sharp overnight decline in South Korea may not signal a change in the company’s underlying outlook.
The Korean chipmaker, which is the world’s largest supplier of high-bandwidth memory to NVIDIA, delivered a strong U.S. market debut on Friday before falling into bear-market territory in Seoul. Cramer argued that the selloff reflects short-term trading psychology rather than weakening demand for HBM.
South Korea’s Market Is “Divorced” From the Fundamentals Speaking with David Faber, Cramer questioned how Korean investors price SK Hynix. “I would say that their market seems to lack a true pricing discovery in that it seems… I’m not saying it’s fixed. I do think that there is a mob that buys it, a mob that sells it,” Cramer said. He went further: “I just say, you know what? I have come to believe that that market is divorced from anything I’ve seen. It doesn’t seem to be related to anything.”
Cramer pointed to the shift toward multi-year contracts as evidence the memory cycle may have structurally changed. “I continue to think it is secular because you’re getting longer-term agreements. That’s what Micron’s got. That’s exactly what Sanjay Mehrotra, CEO of Micron, said on my show,” he said.
Micron Is the Clearest U.S. Winner From the HBM Boom In Micron Technology’s (NASDAQ:MU | MU Price Prediction) fiscal Q3 2026 report filed June 24, 2026, Micron posted revenue of $41.46 billion, up 345.7% year over year, and non-GAAP EPS of $25.11. Non-GAAP gross margin reached 84.9%, and management guided Q4 revenue to $50.0 billion plus or minus $1.0 billion.
Mehrotra tied the results directly to the contract structure Cramer referenced: “We believe our multi-year Strategic Customer Agreements will significantly enhance the durability and predictability of Micron’s strong financial performance.”
July 16 is the Final Day to Tap Into the Lithium Boom (sponsor)
General Motors, POSCO, and 50,000+ everyday investors have already backed lithium producer EnergyX.
Here's why you should do the same before their July 16 investment deadline: lithium prices are up 75% this year, with demand projected to grow a staggering 5X by 2040.
With tech that can recover up to 3X more lithium than traditional methods, EnergyX is preparing to unlock up to 15M+ tons. Become a private-stage EnergyX investor before the July 16 deadline.
NVIDIA Creates the Demand, While Broadcom Expands the Opportunity NVIDIA (NASDAQ:NVDA) sits on the other side of every HBM stack SK Hynix ships. In Q1 FY2027, NVIDIA reported revenue of $81.62 billion, up 85.2% year over year, with Data Center revenue of $75.25 billion, up 92%. Total supply-related commitments hit $119.0 billion, the clearest signal that hyperscaler orders extend well into 2027. CEO Jensen Huang framed it as “the largest infrastructure expansion in human history.”
Broadcom (NASDAQ:AVGO) rounds out the AI silicon complex. Its most recent quarter delivered AI semiconductor revenue of $10.8 billion, up 143% year over year, with CEO Hock Tan guiding Q3 AI revenue to $16.0 billion. Shares are up 46.3% over the past year.
Our Free Report: 7 Stocks Powering the AI Boom showcases some of the picks-and-shovels companies besides chip companies supplying the AI gold rush.
SK Hynix’s U.S. Listing Gives Investors Another Way to Invest in AI SK Hynix’s $26.5 billion U.S. listing gives American investors direct access to one of the world’s largest suppliers of high-bandwidth memory. While NAND prices declined slightly over the past week, demand for DRAM, including HBM used in AI chips, remains strong.
The key point is that SK Hynix’s overnight moves in South Korea may reflect short-term market sentiment more than changes in AI demand. Micron’s long-term contracts, NVIDIA’s supply commitments, and Broadcom’s growing AI business offer a clearer view of the underlying market. Micron’s fiscal fourth-quarter report in September will provide the next major update.
Meet America's Newest $1b Unicorn (Sponsor) A US startup just passed a $1 billion private valuation, joining billion-dollar private companies like OpenAI and ByteDance. Unlike those other unicorns, you can invest in EnergyX right now; but only until July 16.
Over 50,000 people already have, along with global giants like General Motors and POSCO.
Here's why there's so much interest: EnergyX's patented tech can recover up to 3X more lithium than traditional methods. That's a big deal, as demand for lithium is expected to 5X current production levels by 2040. Become an early-stage EnergyX shareholder before the 7/16 investment deadline.
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- Directors of A. O. Smith Corporation (NYSE: AOS) today declared a regular quarterly cash dividend of $.36 per share on the company's Common Stock and Class A Common Stock.
The dividend is payable on Monday, Aug. 17 to shareholders of record Friday, July 31, 2026.
About A. O. Smith
A. O. Smith Corporation, with headquarters in Milwaukee, Wisconsin, is a global leader applying innovative technology and energy-efficient solutions to products manufactured and marketed worldwide. Listed on the New York Stock Exchange (NYSE: AOS), the company is one of the world's leading manufacturers of residential and commercial water heating equipment and boilers, as well as a manufacturer of water treatment and water management products. For more information, visit www.aosmith.com.
In the latest close session, Archer Daniels Midland (ADM - Free Report) was up +2.03% at $82.04. The stock's performance was ahead of the S&P 500's daily loss of 0.79%. Meanwhile, the Dow experienced a drop of 0.26%, and the technology-dominated Nasdaq saw a decrease of 1.55%.
Shares of the agribusiness giant have appreciated by 0.21% over the course of the past month, outperforming the Consumer Staples sector's gain of 0.06%, and lagging the S&P 500's gain of 4.28%.
The upcoming earnings release of Archer Daniels Midland will be of great interest to investors. It is anticipated that the company will report an EPS of $1.28, marking a 37.63% rise compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $22.38 billion, up 5.72% from the prior-year quarter.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $4.81 per share and revenue of $84.49 billion. These totals would mark changes of +40.23% and +5.26%, respectively, from last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Archer Daniels Midland. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 6.4% higher. Archer Daniels Midland presently features a Zacks Rank of #2 (Buy).
With respect to valuation, Archer Daniels Midland is currently being traded at a Forward P/E ratio of 16.74. This expresses a premium compared to the average Forward P/E of 13.52 of its industry.
The Agriculture - Operations industry is part of the Consumer Staples sector. This industry currently has a Zacks Industry Rank of 109, which puts it in the top 45% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Coinbase Global, Inc. (COIN - Free Report) ended the recent trading session at $157.37, demonstrating a -1.07% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a loss of 0.79% for the day. Elsewhere, the Dow saw a downswing of 0.26%, while the tech-heavy Nasdaq depreciated by 1.55%.
The company's shares have seen a decrease of 0.44% over the last month, not keeping up with the Finance sector's gain of 5.64% and the S&P 500's gain of 4.28%.
Market participants will be closely following the financial results of Coinbase Global, Inc. in its upcoming release. The company's earnings per share (EPS) are projected to be $0.32, reflecting a 166.67% increase from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $1.36 billion, reflecting a 9.27% fall from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $1.75 per share and revenue of $5.95 billion, which would represent changes of -56.58% and -17.13%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Coinbase Global, Inc. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 9.27% lower. Coinbase Global, Inc. currently has a Zacks Rank of #3 (Hold).
From a valuation perspective, Coinbase Global, Inc. is currently exchanging hands at a Forward P/E ratio of 90.85. Its industry sports an average Forward P/E of 11, so one might conclude that Coinbase Global, Inc. is trading at a premium comparatively.
Meanwhile, COIN's PEG ratio is currently 6.1. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Financial - Miscellaneous Services stocks are, on average, holding a PEG ratio of 1 based on yesterday's closing prices.
The Financial - Miscellaneous Services industry is part of the Finance sector. This industry, currently bearing a Zacks Industry Rank of 161, finds itself in the bottom 35% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
In the latest trading session, Palo Alto Networks (PANW - Free Report) closed at $330.30, marking a +1.35% move from the previous day. This change outpaced the S&P 500's 0.79% loss on the day. Elsewhere, the Dow saw a downswing of 0.26%, while the tech-heavy Nasdaq depreciated by 1.55%.
The security software maker's shares have seen an increase of 16.56% over the last month, surpassing the Computer and Technology sector's gain of 3.44% and the S&P 500's gain of 4.28%.
The upcoming earnings release of Palo Alto Networks will be of great interest to investors. The company is predicted to post an EPS of $0.97, indicating a 2.11% growth compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $3.35 billion, reflecting a 32.1% rise from the equivalent quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $3.77 per share and a revenue of $11.41 billion, representing changes of +12.87% and +23.71%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Palo Alto Networks. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Palo Alto Networks is currently a Zacks Rank #3 (Hold).
In terms of valuation, Palo Alto Networks is presently being traded at a Forward P/E ratio of 86.45. This valuation marks a premium compared to its industry average Forward P/E of 49.95.
It is also worth noting that PANW currently has a PEG ratio of 6.51. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The average PEG ratio for the Security industry stood at 3.14 at the close of the market yesterday.
The Security industry is part of the Computer and Technology sector. This industry currently has a Zacks Industry Rank of 109, which puts it in the top 45% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Roblox Corporation (NYSE: RBLX) between October 30, 2025 and April 30, 2026, inclusive (the “Class Period”), of the important August 7, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Roblox common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Roblox class action, go to https://rosenlegal.com/cases/roblox-corporation-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 7, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Roblox’s organic growth potential; notably, that Roblox would see a significant slowdown in its growth rates as enrollment in the age verification rollout would quickly taper, compounding the resulting slowdown in on-platform communication, resulting in app store rating reductions and a swift reduction in organic growth. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Roblox class action, go to https://rosenlegal.com/cases/roblox-corporation-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827 [email protected]
www.rosenlegal.com
SAN FRANCISCO, July 13, 2026 (GLOBE NEWSWIRE) -- National shareholder rights firm Hagens Berman is investigating claims alleged in a pending securities class action suit against Roblox Corporation (NYSE: RBLX) and its management following disclosures that the company’s age verification rollout caused significant, undisclosed friction to its user growth and platform engagement.
SUBMIT YOUR RBLX LOSSES TO HBSS NOW
The firm’s investigation focuses on the suit’s claims that Defendants misled investors regarding the operational consequences of the safety-focused initiatives the company had purportedly implemented.
Allegations Concerning Age Verification and Growth:
The suit follows a sharp decline in Roblox’s share price on May 1, 2026, after the company reported its Q1 2026 financial results. The core allegations, which have emerged in recently filed complaint against the company, contend that Roblox failed to disclose that its age-check rollout:
Reduced Platform Engagement: The age verification features hindered on-platform communication, leading to a decline in user interaction.Negatively Impacted Organic Growth: The friction caused by these features resulted in lower app store ratings and a corresponding reduction in organic user sign-ups.Misrepresented Growth Potential: Throughout the class period (October 30, 2025 – April 30, 2026), Roblox characterized the rollout as a “gold standard” implementation while allegedly knowing it would lead to a significant slowdown in user growth. Key Disclosures and Market Impact
April 30, 2026: Roblox revealed a steep deceleration in year-over-year and sequential DAU growth, slashed its 2026 revenue guidance and severely cut its 2026 bookings growth. The company blamed its dismal results on just 51% of Roblox global DAUs having age checked. The company further revealed that “as a result of age check […] we have seen a reduction in app store ratings, and we believe this may be contributing to a reduction in organic sign-ups that typically flow from app stores.” Roblox also said its lowered prospects are the result of “continued friction” resulting from the age-check rollout.Market Correction: The news caused Roblox shares to fall $10.13, or approximately 18.33%, on May 1, 2026, erasing over $6.7 billion in market capitalization. Hagens Berman’s Investigation
“We’re focused on when Roblox and its management knew of the adverse consequences of the age-check rollout and whether they intentionally misled investors about it,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.
Investor Rights and Lead Plaintiff Deadline
Hagens Berman is currently evaluating the claims alleged in the suit brought on behalf of a putative class of investors who purchased Roblox securities between October 30, 2025, and April 30, 2026. If you suffered financial losses on RBLX during the class period, you are encouraged to contact our office to learn more about your legal rights and the ongoing class action litigation. The court-imposed deadline to move for appointment as lead plaintiff is August 7, 2026.
Report your losses nowContact Our Attorneys: [email protected] Hotline: 844-916-0895Hagens Berman’s Roblox Page: www.hbsslaw.com/cases/roblox If you’d like more information and answers to other frequently asked questions about the Roblox case and the firm’s investigation, read more.
Whistleblowers: Persons with non-public information regarding Roblox should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.
In the latest trading session, Strategy (MSTR - Free Report) closed at $92.10, marking a -2.68% move from the previous day. This move lagged the S&P 500's daily loss of 0.79%. At the same time, the Dow lost 0.26%, and the tech-heavy Nasdaq lost 1.55%.
Prior to today's trading, shares of the business software company had lost 23.66% lagged the Finance sector's gain of 5.64% and the S&P 500's gain of 4.28%.
Market participants will be closely following the financial results of Strategy in its upcoming release. The company plans to announce its earnings on July 30, 2026. The company is forecasted to report an EPS of $52.04, showcasing a 59.63% upward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $126.95 million, up 10.88% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $116.7 per share and a revenue of $503.9 million, indicating changes of +866.25% and +5.59%, respectively, from the former year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Strategy. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. As of now, Strategy holds a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Strategy has a Forward P/E ratio of 0.81 right now. For comparison, its industry has an average Forward P/E of 11, which means Strategy is trading at a discount to the group.
The Financial - Miscellaneous Services industry is part of the Finance sector. This industry, currently bearing a Zacks Industry Rank of 161, finds itself in the bottom 35% echelons of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
In the latest close session, HP (HPQ - Free Report) was up +2.27% at $24.77. This move outpaced the S&P 500's daily loss of 0.79%. On the other hand, the Dow registered a loss of 0.26%, and the technology-centric Nasdaq decreased by 1.55%.
Heading into today, shares of the personal computer and printer maker had lost 4.04% over the past month, lagging the Computer and Technology sector's gain of 3.44% and the S&P 500's gain of 4.28%.
The investment community will be closely monitoring the performance of HP in its forthcoming earnings report. The company's earnings per share (EPS) are projected to be $0.66, reflecting a 12% decrease from the same quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $14.62 billion, up 4.91% from the prior-year quarter.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $2.98 per share and revenue of $58.27 billion. These totals would mark changes of -4.49% and +5.39%, respectively, from last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for HP. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. At present, HP boasts a Zacks Rank of #3 (Hold).
In terms of valuation, HP is presently being traded at a Forward P/E ratio of 8.13. This expresses a discount compared to the average Forward P/E of 23.17 of its industry.
We can additionally observe that HPQ currently boasts a PEG ratio of 4.09. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As the market closed yesterday, the Computer - Micro Computers industry was having an average PEG ratio of 2.74.
The Computer - Micro Computers industry is part of the Computer and Technology sector. With its current Zacks Industry Rank of 17, this industry ranks in the top 7% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
In the latest close session, Warner Bros. Discovery (WBD - Free Report) was up +1.88% at $27.09. The stock outperformed the S&P 500, which registered a daily loss of 0.79%. At the same time, the Dow lost 0.26%, and the tech-heavy Nasdaq lost 1.55%.
Shares of the operator of cable TV channels such as TLC and Animal Planet have depreciated by 1.45% over the course of the past month, underperforming the Consumer Discretionary sector's gain of 0.62%, and the S&P 500's gain of 4.28%.
The investment community will be paying close attention to the earnings performance of Warner Bros. Discovery in its upcoming release. The company's earnings per share (EPS) are projected to be -$0.12, reflecting a 119.05% decrease from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $9.33 billion, down 4.9% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of -$1.07 per share and a revenue of $37.04 billion, demonstrating changes of -468.97% and -0.69%, respectively, from the preceding year.
Any recent changes to analyst estimates for Warner Bros. Discovery should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Warner Bros. Discovery currently has a Zacks Rank of #3 (Hold).
The Broadcast Radio and Television industry is part of the Consumer Discretionary sector. Currently, this industry holds a Zacks Industry Rank of 69, positioning it in the top 29% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in the U.S.)
U.S. launch of LEQEMBI IQLIK as an initiation dose planned for late August 2026
, /PRNewswire/ -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for a once‑weekly lecanemab‑irmb subcutaneous injection (brand name: LEQEMBI IQLIK®) as an initiation dose for the treatment of early Alzheimer's disease.
Experience the full interactive Multichannel News Release here: https://www.multivu.com/Eisai/9406151-en-fda-approves-leqembi-for-early-alzheimers-disease
LEQEMBI IQLIK is administered via an autoinjector, introducing a convenient alternative to intravenous (IV) dosing from the start of treatment. For initiation, the approved regimen is 500 mg given once weekly as two 250 mg injections, each delivered in approximately 15 seconds. LEQEMBI IQLIK may also be used for maintenance dosing at 360 mg once weekly after 18 months of IV or subcutaneous treatment. Throughout the entire treatment course – from initiation through maintenance – patients may receive LEQEMBI either as IV infusion or as subcutaneous (SC) injection with LEQEMBI IQLIK. Patients may also switch from IV to SC administration, or vice versa, providing greater convenience and flexibility in LEQEMBI administration.
LEQEMBI is indicated in the United States for adults with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease, collectively referred to as early Alzheimer's disease. MCI due to AD is the earliest symptomatic stage of Alzheimer's disease and can appear with subtle symptoms such as forgetfulness, confusion, or feeling at a loss for words.
Clinical Data Supporting FDA Approval of Subcutaneous Initiation Dosing
The FDA approval of LEQEMBI IQLIK as an initiation dose is supported by a comprehensive clinical data package evaluating SC administration of lecanemab across multiple studies and a range of dosing regimens. Sub‑studies within the Phase 3 Clarity AD long‑term extension (LTE), following the 18‑month core study in individuals with early Alzheimer's disease, showed:
Once‑weekly subcutaneous administration achieved exposure equivalent to intravenous dosing, supporting similar clinical (efficacy) and biomarker (amyloid removal) benefits. The rate of exposure-related adverse events such as ARIA-E with SC administration is expected to be comparable with IV administration. There was no increase in isolated ARIA-H (i.e., ARIA-H in patients who did not also experience ARIA-E) for LEQEMBI compared to placebo. The overall safety profile of SC administration was generally similar to intravenous administration. Injection-related reactions were observed with subcutaneous LEQEMBI, most of which were localized, while systemic reactions were less frequently observed. "The approval of LEQEMBI IQLIK for initiation dosing marks a new era of Alzheimer's treatments," said Howard Fillit, MD, Co-Founder and Chief Science Officer Emeritus of the Alzheimer's Drug Discovery Foundation (ADDF). "For the first time, patients and their care partners have meaningful choice in how anti-amyloid treatment is delivered. As treatment approaches continue to expand, innovations in drug delivery will play a critical role in improving access to therapies, supporting the investigation of potential combination treatments, and advancing a precision medicine approach to Alzheimer's care."
Expanding Treatment Flexibility Across the Alzheimer's Disease Care Pathway
The approval of LEQEMBI IQLIK as a subcutaneous initiation dose provides patients and care partners with the only at-home administration option throughout the Alzheimer's disease treatment journey which could support access and delivery of care across healthcare settings. Subcutaneous administration may:
Reduce the burden of clinic visits currently associated with anti-amyloid therapy for patients and care partners Reduce reliance on infusion and associated healthcare resources Decrease treatment preparation and administration time, and nursing monitoring requirements Preserve infusion capacity for patients who prefer or require intravenous therapy Insights from an autoinjector acceptability study indicated that 94% of patients with early Alzheimer's disease and their care partners found the LEQEMBI IQLIK device easy to use, with high levels of satisfaction and confidence in using it in an at-home setting.*
Support for Patients
The LEQEMBI CompanionTM program offers help with understanding insurance coverage and potential out-of-pocket costs, and identifying financial support programs, including the LEQEMBI Copay Assistance Program for eligible patients.
To further support access to LEQEMBI for certain patients who need help paying for their medicines, Eisai's Patient Assistance Program (PAP) will provide LEQEMBI and LEQEMBI IQLIK at no cost, for eligible uninsured patients, who meet financial need and other program criteria.
LEQEMBI IQLIK for initiation dosing is expected to be available in late August 2026 in the U.S. Patients will receive LEQEMBI IQLIK from a specialty pharmacy.
Eisai serves as the lead for lecanemab's development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.
*Based on in-person interviews of 50 patients with early AD and 50 care partners currently assisting people with early AD. Participants were given the opportunity to interact with a training autoinjector device (containing no needles or medication) and an injection pad, then asked to answer computer-based surveys about their experience, including "How difficult or easy was it to use the self-injection device?"
INDICATION
LEQEMBI® is indicated for the treatment of Alzheimer's disease (AD). Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.
• Monoclonal antibodies directed against aggregated forms of beta amyloid, including LEQEMBI, can cause ARIA, characterized as ARIA with edema (ARIA-E) and ARIA with hemosiderin deposition (ARIA-H). Incidence and timing of ARIA vary among treatments. ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events, including seizure and status epilepticus, can occur. ARIA can be fatal. Serious intracerebral hemorrhages (ICH) >1 cm, some of which have been fatal, have been observed with this class of medications. Because ARIA-E can cause focal neurologic deficits that can mimic an ischemic stroke, consider whether such symptoms could be due to ARIA-E before giving thrombolytic therapy to a patient being treated with LEQEMBI.
o Apolipoprotein E ε4 (ApoE ε4) Homozygotes: Patients who are ApoE ε4 homozygotes (~15% of patients with AD) treated with this class of medications have a higher incidence of ARIA, including symptomatic, serious, and severe radiographic ARIA, compared to heterozygotes and noncarriers. Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA. Prior to testing, prescribers should discuss with patients the risk of ARIA across genotypes and the implications of genetic testing results. Prescribers should inform patients that if genotype testing is not performed, they can still be treated with LEQEMBI; however, it cannot be determined if they are ApoE ε4 homozygotes and at higher risk for ARIA.
• Consider the benefit of LEQEMBI for the treatment of AD and the potential risk of serious ARIA events when deciding to initiate treatment with LEQEMBI.
CONTRAINDICATION
Contraindicated in patients with serious hypersensitivity to lecanemab-irmb or to any of the excipients. Reactions have included angioedema and anaphylaxis.
WARNINGS AND PRECAUTIONS
AMYLOID-RELATED IMAGING ABNORMALITIES
Medications in this class, including LEQEMBI, can cause ARIA-E, which can be observed on MRI as brain edema or sulcal effusions, and ARIA-H, which includes microhemorrhage and superficial siderosis. ARIA can occur spontaneously in patients with AD, particularly in patients with MRI findings suggestive of cerebral amyloid angiopathy (CAA), such as pretreatment microhemorrhage or superficial siderosis. ARIA-H generally occurs with ARIA-E. Reported ARIA symptoms may include headache, confusion, visual changes, dizziness, nausea, and gait difficulty. Focal neurologic deficits may also occur. Symptoms usually resolve over time.
Incidence of ARIA
Symptomatic ARIA occurred in 3% and serious ARIA symptoms in 0.7% with LEQEMBI. Clinical ARIA symptoms resolved in 79% of patients during the period of observation. ARIA, including asymptomatic radiographic events, was observed: LEQEMBI, 21%; placebo, 9%. ARIA-E was observed: LEQEMBI, 13%; placebo, 2%. ARIA-H was observed: LEQEMBI, 17%; placebo, 9%. No increase in isolated ARIA-H was observed for LEQEMBI vs placebo.
Incidence of ICH
ICH >1 cm in diameter was reported in 0.7% with LEQEMBI vs 0.1% with placebo. Fatal events of ICH in patients taking LEQEMBI have been observed.
Risk Factors of ARIA and ICH
ApoE ε4 Carrier Status
Of the patients taking LEQEMBI, 16% were ApoE ε4 homozygotes, 53% were heterozygotes, and 31% were noncarriers. With LEQEMBI, ARIA was higher in ApoE ε4 homozygotes (LEQEMBI: 45%; placebo: 22%) than in heterozygotes (LEQEMBI: 19%; placebo: 9%) and noncarriers (LEQEMBI: 13%; placebo: 4%). Symptomatic ARIA-E occurred in 9% of ApoE ε4 homozygotes vs 2% of heterozygotes and 1% of noncarriers. Serious ARIA events occurred in 3% of ApoE ε4 homozygotes and in ~1% of heterozygotes and noncarriers. The recommendations on management of ARIA do not differ between ApoE ε4 carriers and noncarriers.
Radiographic Findings of CAA
Neuroimaging findings that may indicate CAA include evidence of prior ICH, cerebral microhemorrhage, and cortical superficial siderosis. CAA has an increased risk for ICH. The presence of an ApoE ε4 allele is also associated with CAA.
The baseline presence of at least 2 microhemorrhages or the presence of at least 1 area of superficial siderosis on MRI, which may be suggestive of CAA, have been identified as risk factors for ARIA. Patients were excluded from Clarity AD for the presence of >4 microhemorrhages and additional findings suggestive of CAA (prior cerebral hemorrhage >1 cm in greatest diameter, superficial siderosis, vasogenic edema) or other lesions (aneurysm, vascular malformation) that could potentially increase the risk of ICH.
Concomitant Antithrombotic or Thrombolytic Medication
In Clarity AD, baseline use of antithrombotic medication (aspirin, other antiplatelets, or anticoagulants) was allowed if the patient was on a stable dose. Most exposures were to aspirin. Antithrombotic medications did not increase the risk of ARIA with LEQEMBI. The incidence of ICH: 0.9% in patients taking LEQEMBI with a concomitant antithrombotic medication vs 0.6% with no antithrombotic and 2.5% in patients taking LEQEMBI with an anticoagulant alone or with antiplatelet medication such as aspirin vs none in patients receiving placebo.
Fatal cerebral hemorrhage has occurred in 1 patient taking an anti-amyloid monoclonal antibody in the setting of focal neurologic symptoms of ARIA and the use of a thrombolytic agent.
Additional caution should be exercised when considering the administration of antithrombotics or a thrombolytic agent (e.g., tissue plasminogen activator) to a patient already being treated with LEQEMBI. Because ARIA-E can cause focal neurologic deficits that can mimic an ischemic stroke, treating clinicians should consider whether such symptoms could be due to ARIA-E before giving thrombolytic therapy in a patient being treated with LEQEMBI.
Caution should be exercised when considering the use of LEQEMBI in patients with factors that indicate an increased risk for ICH and, in particular, patients who need to be on anticoagulant therapy or patients with findings on MRI that are suggestive of CAA.
Radiographic Severity With LEQEMBI
Most ARIA-E radiographic events occurred within the first 7 doses, although ARIA can occur at any time, and patients can have >1 episode. Maximum radiographic severity of ARIA-E with LEQEMBI was mild in 4%, moderate in 7%, and severe in 1% of patients. Resolution on MRI occurred in 52% of ARIA-E patients by 12 weeks, 81% by 17 weeks, and 100% overall after detection. Maximum radiographic severity of ARIA-H microhemorrhage with LEQEMBI was mild in 9%, moderate in 2%, and severe in 3% of patients; superficial siderosis was mild in 4%, moderate in 1%, and severe in 0.4% of patients. With LEQEMBI, the rate of severe radiographic ARIA-E was highest in ApoE ε4 homozygotes (5%) vs heterozygotes (0.4%) or noncarriers (0%). With LEQEMBI, the rate of severe radiographic ARIA-H was highest in ApoE ε4 homozygotes (13.5%) vs heterozygotes (2.1%) or noncarriers (1.1%).
Monitoring and Dose Management Guidelines
Baseline brain MRI and periodic monitoring with MRI are recommended. Enhanced clinical vigilance for ARIA is recommended during the first 14 weeks of treatment. Depending on ARIA-E and ARIA-H clinical symptoms and radiographic severity, use clinical judgment when considering whether to continue dosing or to temporarily or permanently discontinue LEQEMBI. If a patient experiences ARIA symptoms, clinical evaluation should be performed, including MRI if indicated. If ARIA is observed on MRI, careful clinical evaluation should be performed prior to continuing treatment.
HYPERSENSITIVITY REACTIONS
Hypersensitivity reactions, including angioedema, bronchospasm, and anaphylaxis, have occurred with LEQEMBI. Promptly discontinue the infusion upon the first observation of any signs or symptoms consistent with a hypersensitivity reaction and initiate appropriate therapy.
INFUSION-RELATED REACTIONS (IRRs)
IRRs were observed—LEQEMBI: 26%; placebo: 7%—and most cases with LEQEMBI (75%) occurred with the first infusion. IRRs were mostly mild (69%) or moderate (28%). Symptoms included fever and flu-like symptoms (chills, generalized aches, feeling shaky, and joint pain), nausea, vomiting, hypotension, hypertension, and oxygen desaturation.
IRRs can occur during or after the completion of infusion. In the event of an IRR during the infusion, the infusion rate may be reduced or discontinued, and appropriate therapy initiated as clinically indicated. Consider prophylactic treatment prior to future infusions with antihistamines, acetaminophen, nonsteroidal anti-inflammatory drugs, or corticosteroids.
ADVERSE REACTIONS
The most common adverse reactions reported in ≥5% with LEQEMBI infusion every 2 weeks and ≥2% higher than placebo were IRRs (LEQEMBI: 26%; placebo: 7%), ARIA-H (LEQEMBI: 14%; placebo: 8%), ARIA-E (LEQEMBI: 13%; placebo: 2%), headache (LEQEMBI: 11%; placebo: 8%), superficial siderosis of central nervous system (LEQEMBI: 6%; placebo: 3%), rash (LEQEMBI: 6%; placebo: 4%), and nausea/vomiting (LEQEMBI: 6%; placebo: 4%) The safety profile of subcutaneous LEQEMBI was similar to intravenous infusion. Subcutaneous dosing was associated with mostly localized (erythema, induration, swelling, heat, pain, pruritus, rash, ecchymosis, nodule, and hematoma) and less frequent systemic (headache, chills, fever, and fatigue) injection-related reactions, majority at first dose when initiating therapy. Localized reactions that were recurrent and/or delayed were observed. Severe localized reactions and cases leading to dose discontinuation or interruption occurred. LEQEMBI (lecanemab-irmb) is available:
Intravenous infusion: 100 mg/mL Subcutaneous injection: 200 mg/mL Please see full Prescribing Information for LEQEMBI, including Boxed WARNING.
Click here to access the LEQEMBI digital library with assets available for download.
MEDIA CONTACTS
Eisai Co., Ltd.
Public Relations Department
TEL: +81 (0)3-3817-5120
Eisai Europe, Ltd.
EMEA Communications Department
+44 (0) 7760 619251
[email protected]
Eisai Inc. (U.S.)
Libby Holman
+1-201-753-1945
[email protected]
Biogen Inc.
Madeleine Shin
+1-781-464-3260
[email protected]
INVESTOR CONTACTS
Eisai Co., Ltd.
Investor Relations Department
TEL: +81 (0) 3-3817-5122
Biogen Inc.
Tim Power
+ 1-781-464-2442
[email protected]
Notes to Editors
About lecanemab (generic name, brand name: LEQEMBI®)
Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).Lecanemab has been approved in 53 countries and regions including Japan, the United States, China, Europe, South Korea, Taiwan, and Saudi Arabia, and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks was approved in 8 countries including the U.S., China, the UK, and others, and applications have been filed in 12 countries and regions. The U.S. FDA approved Eisai's Biologics License Application (BLA) for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025. In November 2025, an application for a subcutaneous injectable formulation in Japan was submitted. In January 2026, the Biologics License Application (BLA) for the subcutaneous formulation was accepted in China. In December 2025, lecanemab (IV) has been included in the "Commercial Insurance Innovative Drug List", recently introduced by the National Healthcare Security Administration (NHSA) of China.
LEQEMBI's approvals in these countries were based on Phase 3 data from Eisai's global placebo-controlled, double-blind, parallel-group, randomized Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results. The primary endpoint was the global cognitive and functional scale, Clinical Dementia Rating Sum of Boxes (CDR-SB). Clarity AD evaluated lecanemab 10 mg/kg bi-weekly IV treatment of early Alzheimer's disease, which involved 1,795 patients (treatment group: 898, placebo group: 897). 95% of patients who completed the core study (18 months) chose to continue in the long-term extension study (LTE), with 478 patients still receiving treatment for four years. In the Clarity AD core clinical study, data showed LEQEMBI IV significantly slowed disease progression at 18 months (27% vs placebo), and the mean change from baseline between the lecanemab treated group and the placebo group after 18 months was -0.45 (P=0.00005) on the primary endpoint of CDR-SB global cognitive and functional scale.
To provide context, a change from 0.5 to 1 on the Clinical Dementia Rating (CDR) score domains of Memory, Community Affairs and Home/Hobbies reflects a shift from mild impairment to loss of independence. This can affect a person's ability to be left alone safely, recall recent events, participate in daily activities, manage household tasks, and engage in hobbies and intellectual interests.
LEQEMBI also rapidly reduced plaque as early as three months (−59.1 CL difference vs placebo in amyloid level at 18 months; P<0.00001).* Additionally, LEQEMBI continued to show benefit over a four-year LTE treatment period; in a subgroup analysis, 81 percent of LEQEMBI patients who stayed on treatment remained in the early AD stages at four years.**
Over three years of treatment, including both the core study and the LTE, data showed lecanemab demonstrated a reduction in cognitive decline—measured by CDR-SB—of 1.01 points compared to the expected decline observed in the Alzheimer's Disease Neuroimaging Initiative (ADNI)** cohort. This benefit grew more pronounced after four years, with a reduction of 1.75 points. Similarly, when benchmarked against the expected decline in the BioFINDER cohort, lecanemab showed a reduction of 1.40 points at three years and an even greater reduction of 2.17 points at the four-year mark. In Clarity AD, the most common adverse events (>10%) in the lecanemab group were infusion reactions, ARIA-H (combined cerebral microhemorrhages, cerebral macrohemorrhages, and superficial siderosis), ARIA-E (edema/effusion), headache, and fall.
*The Centiloid scale is used for amyloid PET, where 0 CL is anchored as the average amyloid in young people without amyloid plaques, and 100 is anchored as the average amyloid level in moderate AD. The baseline centiloid level in CLARITY AD was approximately 78 CL. Plaque negativity is defined as conversion to amyloid PET negative (<30 centiloid, or CL).
**Prespecified subgroup analysis of reduced risk of progression: Progression was defined as CDR-SB score progressing to moderate or severe dementia (≥9.5), based on Kaplan-Meier plots.
About Protofibrils
Protofibrils are thought to be the most toxic Aβ species that contribute to brain damage in AD and play a major role in the cognitive decline of this progressive and devastating disease. Protofibrils can cause neuronal and synaptic damage in the brain, which can subsequently adversely affect cognitive function through multiple mechanisms.18The mechanism by which this occurs has been reported not only by increasing the formation of insoluble Aβ plaques, but also by directly damaging signaling between neurons and other cells. It is believed that reducing protofibrils may reduce neuronal damage and cognitive impairment, potentially preventing the progression of AD.2 About the Collaboration between Eisai and Biogen for AD
Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority. About the Collaboration between Eisai and BioArctic for AD
Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015. About Eisai Co., Ltd.
Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.
For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe. For audiences based in the UK and Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.
About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient's lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTube.
Biogen Safe Harbor
This news release contains forward-looking statements, including about the potential clinical effects of lecanemab; the potential benefits, safety and efficacy of lecanemab; potential regulatory discussions, submissions and approvals and the timing thereof including for lecanemab-irmb (LEQEMBI IQLIK); the treatment of Alzheimer's disease; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "estimate," "expect," "forecast," "goal," "guidance," "hope," "intend," "may," "objective," "plan," "possible," "potential," "predict," "project," "prospect," "should," "target," "will," "would," and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements. These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our corporate strategy; the successful execution of our strategic and growth initiatives, including acquisitions; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission.
These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned "Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.
Digital Media Disclosure
From time to time, we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X account (https://x.com/biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and these social media channels in addition to our press releases, SEC filings, public conference calls and websites, as the information posted on them could be material to investors.
References
Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z. Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706. SOURCE Eisai Inc.
In the latest close session, Riot Platforms, Inc. (RIOT - Free Report) was down 3.7% at $20.19. This change lagged the S&P 500's daily loss of 0.79%. On the other hand, the Dow registered a loss of 0.26%, and the technology-centric Nasdaq decreased by 1.55%.
The company's stock has dropped by 21.21% in the past month, falling short of the Finance sector's gain of 5.64% and the S&P 500's gain of 4.28%.
The investment community will be closely monitoring the performance of Riot Platforms, Inc. in its forthcoming earnings report. On that day, Riot Platforms, Inc. is projected to report earnings of -$0.21 per share, which would represent a year-over-year decline of 136.84%. In the meantime, our current consensus estimate forecasts the revenue to be $148.71 million, indicating a 2.8% decline compared to the corresponding quarter of the prior year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$2.08 per share and a revenue of $647.34 million, signifying shifts of -6.67% and -0.02%, respectively, from the last year.
Investors should also note any recent changes to analyst estimates for Riot Platforms, Inc. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. At present, Riot Platforms, Inc. boasts a Zacks Rank of #3 (Hold).
The Financial - Miscellaneous Services industry is part of the Finance sector. With its current Zacks Industry Rank of 161, this industry ranks in the bottom 35% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Affirm Holdings (AFRM - Free Report) ended the recent trading session at $81.93, demonstrating a -1.79% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily loss of 0.79%. Meanwhile, the Dow experienced a drop of 0.26%, and the technology-dominated Nasdaq saw a decrease of 1.55%.
The operator of digital commerce platform's stock has climbed by 26.07% in the past month, exceeding the Computer and Technology sector's gain of 3.44% and the S&P 500's gain of 4.28%.
The upcoming earnings release of Affirm Holdings will be of great interest to investors. In that report, analysts expect Affirm Holdings to post earnings of $0.33 per share. This would mark year-over-year growth of 65%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $1.11 billion, up 26.39% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $1.23 per share and a revenue of $4.21 billion, indicating changes of +720% and +30.62%, respectively, from the former year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Affirm Holdings. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 2.52% increase. Affirm Holdings is currently a Zacks Rank #3 (Hold).
With respect to valuation, Affirm Holdings is currently being traded at a Forward P/E ratio of 48.05. For comparison, its industry has an average Forward P/E of 19.66, which means Affirm Holdings is trading at a premium to the group.
Also, we should mention that AFRM has a PEG ratio of 3.37. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Internet - Software was holding an average PEG ratio of 1.07 at yesterday's closing price.
The Internet - Software industry is part of the Computer and Technology sector. This industry, currently bearing a Zacks Industry Rank of 104, finds itself in the top 43% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
MEXC, a pioneer in 0-fee digital asset trading, announced the addition of five Ondo tokenized stock and ETF trading pairs to its spot market, the latest expansion of its ongoing collaboration with Ondo Finance. The new pairs cover the semiconductor, energy and AI infrastructure sectors, expanding the range of tokenized U.S. equities available to users and allowing them to trade these assets using USDT.
The trading pairs include tokenized stocks and ETFs tracking Direxion Daily Semiconductor Bull 3X ETF (SOXLON/USDT), Direxion Daily Semiconductor Bear 3X ETF (SOXSON/USDT), Halliburton (HALON/USDT) and Core Scientific (CORZON/USDT), all now open for trading on MEXC’s spot market.
SK hynix completed its Nasdaq listing on July 10, 2026, raising $26.5 billion in one of the largest U.S. listings this year, with shares initially trading under the ticker SKHYV before switching to SKHY on July 13, 2026. The company is a leading global supplier of high-bandwidth memory (HBM) chips, a component in high demand amid the expansion of AI infrastructure. To meet user demand for trending U.S. stocks, MEXC will add SKHYON/USDT, tracking SK hynix (Nasdaq: SKHY), to the spot market at 13:30 on July 13, 2026 (UTC).
Ondo Finance focuses on bringing traditional financial assets on-chain through compliant infrastructure, allowing users to access assets such as U.S. Treasuries, stocks and ETFs in a blockchain-native format, with each tokenized asset backed by the corresponding underlying security held through regulated custodial brokers. This deepened collaboration with Ondo reflects MEXC’s continued build-out in the tokenized real-world asset space. As a one-stop trading platform, MEXC provides users with diverse access to global markets, offering both Ondo’s tokenized stocks and RealStocks, a product that allows users to hold real share ownership and dividends.
About MEXC MEXC is the world’s fastest-growing cryptocurrency exchange, trusted by more than 40 million users across 170+ markets. Built on a user-first philosophy, MEXC offers industry-leading 0-fee trading and access to over 3,000 digital assets. As the Gateway to Infinite Opportunities, MEXC provides a single platform where users can easily trade cryptocurrencies alongside tokenized assets, including stocks, ETFs, commodities, and precious metals.
MEXC Official Website｜ X ｜ Telegram ｜How to Sign Up on MEXC
This content does not constitute investment advice. Given the highly volatile nature of the cryptocurrency market, investors are encouraged to carefully assess market fluctuations, project fundamentals, and potential financial risks before making any trading decisions.
Source
Disclaimer: TheNewsCrypto does not endorse any content on this page. The content depicted in this Press Release does not represent any investment advice. TheNewsCrypto recommends our readers to make decisions based on their own research. TheNewsCrypto is not accountable for any damage or loss related to content, products, or services stated in this Press Release.
In the latest close session, Fortinet (FTNT - Free Report) was up +1.97% at $160.62. The stock's change was more than the S&P 500's daily loss of 0.79%. At the same time, the Dow lost 0.26%, and the tech-heavy Nasdaq lost 1.55%.
Shares of the network security company witnessed a gain of 7.66% over the previous month, beating the performance of the Computer and Technology sector with its gain of 3.44%, and the S&P 500's gain of 4.28%.
The investment community will be closely monitoring the performance of Fortinet in its forthcoming earnings report. The company is scheduled to release its earnings on July 29, 2026. The company is predicted to post an EPS of $0.75, indicating a 17.19% growth compared to the equivalent quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $1.88 billion, up 15.44% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates project earnings of $3.15 per share and a revenue of $7.8 billion, demonstrating changes of +14.13% and +14.65%, respectively, from the preceding year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Fortinet. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.68% higher. As of now, Fortinet holds a Zacks Rank of #3 (Hold).
Digging into valuation, Fortinet currently has a Forward P/E ratio of 49.95. This represents no noticeable deviation compared to its industry average Forward P/E of 49.95.
Also, we should mention that FTNT has a PEG ratio of 3.81. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As the market closed yesterday, the Security industry was having an average PEG ratio of 3.14.
The Security industry is part of the Computer and Technology sector. This industry currently has a Zacks Industry Rank of 109, which puts it in the top 45% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
In the latest trading session, Cameco (CCJ - Free Report) closed at $90.20, marking a -6.03% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 0.79% for the day. Elsewhere, the Dow saw a downswing of 0.26%, while the tech-heavy Nasdaq depreciated by 1.55%.
Prior to today's trading, shares of the uranium producer had lost 4.92% lagged the Oils-Energy sector's loss of 3.33% and the S&P 500's gain of 4.28%.
Investors will be eagerly watching for the performance of Cameco in its upcoming earnings disclosure. On that day, Cameco is projected to report earnings of $0.31 per share, which would represent a year-over-year decline of 39.22%. In the meantime, our current consensus estimate forecasts the revenue to be $534.36 million, indicating a 15.69% decline compared to the corresponding quarter of the prior year.
For the full year, the Zacks Consensus Estimates project earnings of $1.2 per share and a revenue of $2.39 billion, demonstrating changes of +16.5% and -4.07%, respectively, from the preceding year.
Investors should also note any recent changes to analyst estimates for Cameco. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.96% lower within the past month. As of now, Cameco holds a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Cameco has a Forward P/E ratio of 80.1 right now. Its industry sports an average Forward P/E of 17.3, so one might conclude that Cameco is trading at a premium comparatively.
Meanwhile, CCJ's PEG ratio is currently 1.69. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As the market closed yesterday, the Alternative Energy - Other industry was having an average PEG ratio of 2.02.
The Alternative Energy - Other industry is part of the Oils-Energy sector. This group has a Zacks Industry Rank of 104, putting it in the top 43% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
, /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ZoomInfo Technologies Inc. (NASDAQ: GTM) securities between November 3, 2025 and May 11, 2026. ZoomInfo Technologies Inc., together with its subsidiaries, provides go-to-market intelligence and engagement platform for sales, marketing, operations, and recruiting professionals in the United States and internationally.
For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
What is the class period? November 3, 2025 – May 11, 2026
What are the allegations? Robbins LLP is Investigating Allegations that ZoomInfo Technologies Inc. (GMT) Misled Investors Regarding its Business Prospects
According to the complaint, during the class period, defendants provided investors with material information concerning ZoomInfo's growth potential for the fiscal year 2026. Defendants' statements included, among other things, confidence in the Company's projected revenue outlook and anticipated growth of its legacy and emerging AI-driven products, core software business and sustained improvement in net revenue retention. Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of ZoomInfo's slowing growth, its legacy seat-based subscription platforms, and weakening customer retention in its down-market segment. Further, the Company minimized concerns that customers were moving towards consumption-based usage models and developing internal AI-driven go-to-market solutions.
Plaintiff alleges that on May 11, 2026, ZoomInfo announced its first quarter 2026 financial results, unveiling a sharp decline in growth outlook and lowering its 2026 full year financial guidance. On this news, ZoomInfo's stock price fell to $4.06 per share on May 12, 2026.
What can shareholders do now? You may be eligible to participate in the class action against ZoomInfo Technologies Inc. Shareholders who wish to serve as lead plaintiff for the class must submit their papers to the court by August 24, 2026. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.
To be notified if a class action against ZoomInfo Technologies Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
Contact:
Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
[email protected]
(800) 350-6003
www.robbinsllp.com
Shares of Wix.com (WIX +4.44%) have fallen 56% in the first half of 2026, according to data from S&P Global Market Intelligence. The website builder is at a turning point due to advances in artificial intelligence (AI) that could disrupt its existing business. Revenue keeps growing, but so far, Wix has not been able to tamp down the narrative that new coding tools will disrupt its drag-and-drop platform.
The stock is now down 85% from its highs, but it continues to post solid growth. Does that make the stock a buy-the-dip candidate right now?
Today's Change
(
4.44
%) $
2.23
Current Price
$
52.37
Large expenses and an AI narrative As a website-building platform for small businesses, there is a strong Wall Street theme that new software tools like Claude Code will replace specific software like Wix. Wix has responded to the AI revolution with tools of its own, such as the homegrown acquisition of Base44, an AI application builder, and the internally developed Wix Harmony chatbot website creator.
Revenue has grown over the last few quarters, especially because of Base44's monstrous growth. Revenue was up 14% year-over-year to $541 million in Q1. However, it recently reduced its full-year revenue guidance by $25 million due to a slowdown in its partners' business, which involves third-party designers using Wix's tools to build websites/software for clients. The fear is that Wix is being replaced by AI tools.
Adding to the business's fears is the fact that Wix's expenses grew massively last quarter due to acquisition bonuses for Base44 and two Super Bowl commercial slots. While one could argue that buying Super Bowl commercials is a waste of time, these are one-time expenses that will not be repeated this year and have nothing to do with AI disruption. In fact, due to cost-saving measures, Wix is now expecting full-year adjusted free cash flow of $420 million, $20 million above its previous estimate.
Image source: Getty Images.
Should you buy the dip? For anyone looking at Wix stock, management has already been doing its own form of "buying the dip" by repurchasing 30% of its outstanding shares in an April tender offer. This will significantly reduce shares outstanding and increase long-term earnings per share and free cash flow per share.
Wix currently has a market cap of just $2.2 billion and is guiding for $420 million in free cash flow in 2026. Unless you think AI software will kill this business next year, the stock looks mighty cheap after this collapse, and could be worth buying the dip on at current prices.
Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Wix.com. The Motley Fool has a disclosure policy.
Wedbush Securities tech strategist Dan Ives argued on CNBC on Monday that memory chips have become the most valuable slice of the AI supply chain, and that SK Hynix’s blockbuster U.S. listing debut on Friday is the clearest signal yet that capital is rotating toward American-listed AI infrastructure names. “Those are the golden child really of this AI revolution. The reality is you’re not going to have equilibrium in terms of demand and supply at least until 2028.”
Ives quantified the supply and demand imbalance he sees: “We continue to think demand [to] supply 15 to 1 in terms of the chips,” he said, adding that for the first time in 30 years, the U.S. is ahead of China in tech, a shift he expects will draw more foreign listings to New York.
Micron Is the Purest U.S. Play on the AI Memory Shortage The clearest expression of the memory rerating is Micron Technology (NASDAQ:MU | MU Price Prediction). Shares are up 243.33% year to date and 696.76% over the past year, carrying the company to a $1.1 trillion market cap. Fiscal Q3 revenue reached $41.456 billion, up 345.72% year over year, with GAAP gross margin expanding to 84.6% and non-GAAP EPS of $25.11 beating consensus expectations. Guidance calls for Q4 revenue of $50.0 billion ± $1.0 billion and roughly 86% gross margin.
CEO Sanjay Mehrotra told investors that “AI demand is driving DRAM and NAND data center bits TAM to exceed 50% of the industry TAM for the first time in calendar 2026” and that Micron can currently fulfill only “50% to two-thirds” of some customers’ demand. That is the supply squeeze Ives is monetizing thematically.
Why Dan Ives Still Likes Nvidia Ives argued that NVIDIA (NASDAQ:NVDA) and the hyperscalers have become “the shiny new toy, shiny new object in terms of memory. The ones that are actually at the center, whether it’s the hyperscalers or Nvidia, those are almost in the penalty box.”
Ives believes Nvidia still plays a central role in the AI industry: “There’s one chip in the world fueling the AI revolution, and that’s led by the godfather of AI, Nvidia. Where is memory without Nvidia? Where’s memory without the hyperscalers?”
Ives cited that NVIDIA trades at its lowest valuation since 2019, even as Q1 FY2027 revenue hit $81.61 billion, with Data Center at $75.25 billion. The stock trades at a forward P/E of 24 and closed at $203.53 on Monday against an analyst target price of $301.62.
Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.
For investors mapping the AI stack, our team has covered the theme in our Free Report: 7 Stocks Powering the AI Boom.
TSMC Confirms the AI Chip Boom Is Still Accelerating Ives pointed to Taiwan Semiconductor Manufacturing (NYSE:TSM) as a confirmation signal that the AI boom is accelerating. June revenue jumped 67.9% year over year to NT$442.68 billion, with first-half 2026 cumulative revenue of NT$2,404.48 billion, up 35.6%. Q2 results land July 16, 2026, three days from Ives’s segment. The stock is up 43.57% year-to-date.
Companies Making Money From the Memory-Chip Supercycle Broadcom (NASDAQ:AVGO) posted Q2 AI semiconductor revenue of $10.80 billion, up 143% year over year, and guided Q3 AI revenue to $16.00 billion, over 200% growth. CEO Hock Tan tied the growth to “increasing demand for custom AI accelerators and AI networking.”
Lam Research (NASDAQ:LRCX) sells the deposition and etch tools that make HBM possible. Fiscal Q3 revenue reached $5.84 billion, up 23.8% year over year, with June-quarter guidance of $6.60 billion. South Korea and Taiwan together account for 46% of revenue, direct exposure to the SK Hynix and TSMC HBM ramps. Shares are up 105.04% year to date.
Key Takeaways Ives’s broader argument is that memory chips have become one of the most valuable and supply-constrained parts of the AI infrastructure buildout. Micron offers the clearest direct exposure among U.S. companies, while NVIDIA, TSMC, Broadcom, and Lam Research each provide exposure to a different layer of the same investment cycle.
The next major signals to watch include TSMC’s July 16 earnings report, the start of HBM4E volume production in 2027, and any additional U.S. listings from Asian chipmakers.
Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.
In the latest close session, Lam Research (LRCX - Free Report) was down 5.83% at $329.92. This change lagged the S&P 500's daily loss of 0.79%. Elsewhere, the Dow saw a downswing of 0.26%, while the tech-heavy Nasdaq depreciated by 1.55%.
Heading into today, shares of the semiconductor equipment maker had lost 4.49% over the past month, lagging the Computer and Technology sector's gain of 3.44% and the S&P 500's gain of 4.28%.
Analysts and investors alike will be keeping a close eye on the performance of Lam Research in its upcoming earnings disclosure. The company's earnings report is set to go public on July 29, 2026. The company's upcoming EPS is projected at $1.69, signifying a 27.07% increase compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $6.67 billion, reflecting a 29.04% rise from the equivalent quarter last year.
LRCX's full-year Zacks Consensus Estimates are calling for earnings of $5.68 per share and revenue of $23.19 billion. These results would represent year-over-year changes of +37.2% and +25.77%, respectively.
Investors might also notice recent changes to analyst estimates for Lam Research. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 2.54% increase. Lam Research currently has a Zacks Rank of #2 (Buy).
In terms of valuation, Lam Research is currently trading at a Forward P/E ratio of 44.15. This indicates a discount in contrast to its industry's Forward P/E of 49.67.
Also, we should mention that LRCX has a PEG ratio of 2.07. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The average PEG ratio for the Electronics - Semiconductors industry stood at 1.86 at the close of the market yesterday.
The Electronics - Semiconductors industry is part of the Computer and Technology sector. Currently, this industry holds a Zacks Industry Rank of 46, positioning it in the top 19% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
In the latest close session, Dell Technologies (DELL - Free Report) was down 1.81% at $427.11. The stock's change was less than the S&P 500's daily loss of 0.79%. On the other hand, the Dow registered a loss of 0.26%, and the technology-centric Nasdaq decreased by 1.55%.
Shares of the computer and technology services provider witnessed a gain of 9.96% over the previous month, beating the performance of the Computer and Technology sector with its gain of 3.44%, and the S&P 500's gain of 4.28%.
The upcoming earnings release of Dell Technologies will be of great interest to investors. The company's earnings per share (EPS) are projected to be $4.88, reflecting a 110.34% increase from the same quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $46.48 billion, showing a 56.1% escalation compared to the year-ago quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $18.77 per share and a revenue of $170.55 billion, indicating changes of +82.23% and +50.22%, respectively, from the former year.
Investors should also pay attention to any latest changes in analyst estimates for Dell Technologies. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.75% increase. Dell Technologies presently features a Zacks Rank of #1 (Strong Buy).
From a valuation perspective, Dell Technologies is currently exchanging hands at a Forward P/E ratio of 23.17. This denotes no noticeable deviation relative to the industry average Forward P/E of 23.17.
One should further note that DELL currently holds a PEG ratio of 0.88. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Computer - Micro Computers industry had an average PEG ratio of 2.74 as trading concluded yesterday.
The Computer - Micro Computers industry is part of the Computer and Technology sector. This industry currently has a Zacks Industry Rank of 17, which puts it in the top 7% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Applied Materials (AMAT - Free Report) ended the recent trading session at $575.39, demonstrating a -4.5% change from the preceding day's closing price. This move lagged the S&P 500's daily loss of 0.79%. On the other hand, the Dow registered a loss of 0.26%, and the technology-centric Nasdaq decreased by 1.55%.
The stock of maker of chipmaking equipment has risen by 6.21% in the past month, leading the Computer and Technology sector's gain of 3.44% and the S&P 500's gain of 4.28%.
Investors will be eagerly watching for the performance of Applied Materials in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on August 13, 2026. In that report, analysts expect Applied Materials to post earnings of $3.36 per share. This would mark year-over-year growth of 35.48%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $9 billion, up 23.28% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $12.13 per share and revenue of $33.38 billion, indicating changes of +28.77% and +17.67%, respectively, compared to the previous year.
Investors should also take note of any recent adjustments to analyst estimates for Applied Materials. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.22% higher. Applied Materials is currently sporting a Zacks Rank of #1 (Strong Buy).
Valuation is also important, so investors should note that Applied Materials has a Forward P/E ratio of 49.67 right now. This valuation marks no noticeable deviation compared to its industry average Forward P/E of 49.67.
We can additionally observe that AMAT currently boasts a PEG ratio of 1.53. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Electronics - Semiconductors industry was having an average PEG ratio of 1.86.
The Electronics - Semiconductors industry is part of the Computer and Technology sector. With its current Zacks Industry Rank of 46, this industry ranks in the top 19% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
DocuSign (DOCU - Free Report) ended the recent trading session at $49.87, demonstrating a +1.4% change from the preceding day's closing price. The stock outpaced the S&P 500's daily loss of 0.79%. Meanwhile, the Dow lost 0.26%, and the Nasdaq, a tech-heavy index, lost 1.55%.
The provider of electronic signature technology's shares have seen an increase of 9.22% over the last month, surpassing the Computer and Technology sector's gain of 3.44% and the S&P 500's gain of 4.28%.
The investment community will be paying close attention to the earnings performance of DocuSign in its upcoming release. The company is forecasted to report an EPS of $1.08, showcasing a 17.39% upward movement from the corresponding quarter of the prior year. Meanwhile, our latest consensus estimate is calling for revenue of $868.04 million, up 8.42% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates project earnings of $4.54 per share and a revenue of $3.49 billion, demonstrating changes of +18.23% and +8.53%, respectively, from the preceding year.
Any recent changes to analyst estimates for DocuSign should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, there's been a 1% rise in the Zacks Consensus EPS estimate. Currently, DocuSign is carrying a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that DocuSign has a Forward P/E ratio of 10.83 right now. This expresses a discount compared to the average Forward P/E of 19.66 of its industry.
Meanwhile, DOCU's PEG ratio is currently 0.65. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As of the close of trade yesterday, the Internet - Software industry held an average PEG ratio of 1.07.
The Internet - Software industry is part of the Computer and Technology sector. This industry currently has a Zacks Industry Rank of 104, which puts it in the top 43% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
SAN JOSE, Calif.--(BUSINESS WIRE)--Western Digital Corporation (Nasdaq: WDC) plans to announce its fourth quarter and fiscal year 2026 financial results after the market closes on Wednesday, August 5, 2026. The company will host a conference call with the investment community to discuss these results on August 5, 2026, at 1:30 p.m. Pacific / 4:30 p.m. Eastern. A live audio webcast and a webcast replay of the conference call will be available at investor.wdc.com.
About WD
WD, also known as Western Digital, builds the storage infrastructure that powers certainty in the AI-driven data economy. At the forefront of innovation, WD partners with the world's leading hyperscalers, cloud service providers, and enterprises to enable reliable storage solutions that are proven and trusted at scale. Driven by a culture of innovation and execution, WD helps customers store, protect, and use the world's data with confidence. Follow WD on LinkedIn and learn more at www.wd.com.
Western Digital (WDC - Free Report) closed the most recent trading day at $555.55, moving -4.64% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.79% for the day. Meanwhile, the Dow lost 0.26%, and the Nasdaq, a tech-heavy index, lost 1.55%.
Coming into today, shares of the maker of hard drives for businesses and personal computers had gained 3.49% in the past month. In that same time, the Computer and Technology sector gained 3.44%, while the S&P 500 gained 4.28%.
Analysts and investors alike will be keeping a close eye on the performance of Western Digital in its upcoming earnings disclosure. In that report, analysts expect Western Digital to post earnings of $3.34 per share. This would mark year-over-year growth of 101.2%. Simultaneously, our latest consensus estimate expects the revenue to be $3.7 billion, showing a 42.21% escalation compared to the year-ago quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $10.06 per share and a revenue of $12.88 billion, indicating changes of +104.06% and -3.02%, respectively, from the former year.
It is also important to note the recent changes to analyst estimates for Western Digital. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been a 4.76% rise in the Zacks Consensus EPS estimate. As of now, Western Digital holds a Zacks Rank of #1 (Strong Buy).
In terms of valuation, Western Digital is currently trading at a Forward P/E ratio of 31.26. This represents a premium compared to its industry average Forward P/E of 15.88.
The Computer- Storage Devices industry is part of the Computer and Technology sector. With its current Zacks Industry Rank of 6, this industry ranks in the top 3% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Twelve US states have sued to block Paramount from acquiring Warner Bros. Discovery in a $110bn deal.
The states argued cinemas and moviegoers could face higher prices if the merger goes ahead, as Paramount and Warner Bros. currently compete for the best release dates and screens at thousands of cinemas across the US.
The lawsuit represents a significant obstacle for the deal, which is seen as one of the biggest media mergers in history.
"After this merger, for every dollar generated by wide-release theatrical films and basic cable channels in this country, the combined company will pocket more than a quarter," the states said in the lawsuit.
They added: "This merger, in short, would create a media behemoth."
Paramount said the lawsuit distorts settled antitrust law and is based on a misrepresentation of competition in the entertainment industry.
The deal was cleared by US federal antitrust watchdogs last month, with critics saying Paramount's political connections helped the positive outcome.
More from US
Iran war latest: One dead and eight injured as Tehran targets tankers in Strait of Hormuz, UAE says
Senators demand Pentagon reveals outcome of Minab school strike probe
FBI agents assist investigation after Senator Graham's death
Paramount CEO David Ellison's father, billionaire Oracle co-founder Larry Ellison, has cultivated ties with Republican President Donald Trump.
All the state attorneys general involved in Monday's lawsuit are Democrats.
The deal was cleared by the Department of Justice last month as it said it would benefit workers and consumers.
But Hollywood workers have criticised the deal, fearing it would hurt jobs, while cinema owners opposed it, worrying it would result in fewer films.
Read more from Sky News:
Florida airport renamed after Donald Trump
Did FIFA bend the rules for Trump?
If allowed to move forward with the deal, Paramount would control 27% of the distribution market for films that appear on screens across America, 30% of blockbuster film distribution and 27% of the market for basic cable channels, the states said.
Arizona, Colorado, Connecticut, Massachusetts, Minnesota, Nevada, New Jersey, New Mexico, New York, Oregon and Washington joined the lawsuit alongside California.
The Warner Bros. Water Tower is pictured at Warner Bros. Studios in Burbank on the day it was announced that California and 11 states are suing to block Paramount's $110 billion acquisition of... Purchase Licensing Rights, opens new tab Read more
SummaryCompaniesCalifornia's Bonta says firm brings 'firepower' in antitrustJustice Department cleared transaction after eight-month reviewParamount taps Jeffrey Kessler and other antitrust lawyersWASHINGTON, July 13 (Reuters) - California said on Monday it has hired law firm Milbank to help with its lawsuit seeking to block Paramount’s (PSKY.O), opens new tab merger with Warner Bros (WBD.O), opens new tab, gaining access to top antitrust lawyers who can go toe to toe with Paramount's legal team.
The move also sets up a potential clash between President Donald Trump's administration, which backed the merger, and a firm that decided to settle with Trump when he targeted law firms over their past clients, hiring practices and ties to Trump's perceived enemies.
Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.
California Attorney General Rob Bonta said the state hired Milbank, a major corporate firm, because "we need the firepower." He said California expected to face "an army of high-powered private attorneys" from Paramount.
California’s team from Milbank includes Richard Parker and James Weingarten, a former U.S. government antitrust lawyer on the team that unsuccessfully tried to stop Microsoft’s $69 billion bid for Activision Blizzard.
Jeffrey Kessler of law firm Winston Taylor said he will be lead trial counsel defending the merger for Paramount, which has also hired former U.S. Solicitor General Paul Clement.
The Paramount case sets up a high-profile battle over one of the largest media deals in recent years. It pits California, New York and other Democratic-led states against big and influential corporations whose merger was approved in June by the Republican Trump administration.
Milbank is among the firms that reached agreements last year with Trump to avoid punishing executive orders he issued against prominent law firms over a wide range of issues. Milbank agreed to provide $100 million in free legal services to mutually agreed initiatives.
California and other states criticized the law firms' settlements, saying they yielded to political pressure.
Milbank, the White House and the Justice Department did not immediately respond to requests for comment.
In Monday's lawsuit, California and 11 other states said the merger would give the combined company greater power to raise prices in film and television markets, with the effects ultimately falling on consumers and workers.
The Justice Department in June cleared the transaction after an eight-month review, finding it likely would have a positive effect on competition.
Milbank's attorneys have gone against the administration in other cases since settling with Trump last year.
The firm represented small businesses that sued over Trump's use of emergency powers to impose sweeping tariffs and won a Supreme Court ruling in February striking down the measures.
Milbank and other lawyers also won a ruling in June defeating the administration's lawsuit over the immigration policies of cities in New Jersey.
Reporting by Mike Scarcella; Editing by David Bario and David Gregorio
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Chipotle Mexican Grill remains a dominant fast-casual player with robust revenue growth and premium margins. I maintain my Buy rating on CMG, despite recent underperformance and its premium valuation, as fundamentals remain strong. CMG trades at a 31x forward P/E—about a 97% premium to sector median—yet its fundamentals justify the multiple.
A motorist who was shot dead by an Immigration and Customs Enforcement (ICE) agent in the US state of Maine was the wrong target, authorities have said.
According to immigration rights groups, the man was 26 and originally from Colombia.
Matthew Felling, the spokesman for Maine senator Angus King, said: "In the hours since his press conference with the Maine press corps, Senator King heard back from the Department of Homeland Security Markwayne Mullin who shared with him that the victim of today's federal law enforcement shooting was not the target of the warrant.
"Senator King continues to emphasize the need for a full and transparent investigation."
Senator King previously said Mr Mullin had told him the officer opened fire after the man tried to use his vehicle as a weapon against officers who were pursuing him for deportation in Biddeford.
"He was in a vehicle - pulled out in the vehicle, and the term the secretary used was 'weaponized' the vehicle and was shot by an ICE agent," Senator King said.
The Maine attorney general's office, which is investigating along with the FBI and other agencies, had earlier said initial statements suggest the motorist was trying to flee in the direction of the agent.
More from US
Iran war latest: One dead and eight injured as Tehran targets tankers in Strait of Hormuz, UAE says
Senators demand Pentagon reveals outcome of Minab school strike probe
FBI agents assist investigation after Senator Graham's death
The man was the target of an enforcement operation related to a final order of removal, the office said.
The agent who killed him has been placed on leave.
Datawrapper This content is provided by Datawrapper, which may be using cookies and other technologies. To show you this content, we need your permission to use cookies. You can use the buttons below to amend your preferences to enable Datawrapper cookies or to allow those cookies just once. You can change your settings at any time via the Privacy Options. Unfortunately we have been unable to verify if you have consented to Datawrapper cookies. To view this content you can use the button below to allow Datawrapper cookies for this session only.
It is the second fatality at the hands of ICE in a week, after a man was shot in Houston, Texas.
It is also at least the ninth death from an encounter with federal immigration officials since the start of US President Donald Trump's immigration crackdown.
Daniel Boucher said he looked out his third-floor window after hearing a "pop, pop, pop" sound and saw a small car "turned 90 degrees to the curb" with an SUV behind it.
The driver was wounded and the car started moving down the street until the SUV hit it again, Mr Boucher said.
How Trump reinvented ICE | Sky News Explains
"His face was bloody. His head was bloody," Mr Boucher said.
"I clearly heard the victim say, 'I tried to stop' - clearly heard him say that."
Mr Boucher said he saw an ICE officer bring a medical bag to where the man was lying before an ambulance and fire engine arrived.
At one point, Mr Boucher said, the agent who shot the man walked close to him.
"I was emotional and I just let him have it, and he looked at me and said, 'He tried to run me over', or something to that effect," Mr Boucher said. "I don't remember his exact words."
The man who was killed was authorised to work in the US and had a social security number, according to advocacy groups the Maine Immigrants' Rights Coalition and Presente!.
Read more:
What is ICE and what powers do its agents have?
ICE and the Maine Department of Public Safety were approached for comment by the Associated Press.
Kristen Setera, an FBI spokesperson, said the FBI "responded to assist on-scene immediately following this morning's shooting incident in Biddeford, Maine," but she declined to comment further.
In the latest trading session, Louisiana-Pacific (LPX - Free Report) closed at $72.20, marking a -1.31% move from the previous day. This change lagged the S&P 500's 0.79% loss on the day. Elsewhere, the Dow lost 0.26%, while the tech-heavy Nasdaq lost 1.55%.
Shares of the home construction supplier witnessed a loss of 2.51% over the previous month, trailing the performance of the Construction sector with its gain of 2.79%, and the S&P 500's gain of 4.28%.
The investment community will be paying close attention to the earnings performance of Louisiana-Pacific in its upcoming release. The company is slated to reveal its earnings on August 5, 2026. On that day, Louisiana-Pacific is projected to report earnings of $0.64 per share, which would represent a year-over-year decline of 35.35%. Meanwhile, our latest consensus estimate is calling for revenue of $683 million, down 9.54% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of $2 per share and revenue of $2.57 billion, which would represent changes of -24.53% and -5%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Louisiana-Pacific. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Currently, Louisiana-Pacific is carrying a Zacks Rank of #3 (Hold).
In terms of valuation, Louisiana-Pacific is presently being traded at a Forward P/E ratio of 36.58. Its industry sports an average Forward P/E of 28.6, so one might conclude that Louisiana-Pacific is trading at a premium comparatively.
One should further note that LPX currently holds a PEG ratio of 1.84. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Building Products - Wood was holding an average PEG ratio of 1.53 at yesterday's closing price.
The Building Products - Wood industry is part of the Construction sector. This industry currently has a Zacks Industry Rank of 171, which puts it in the bottom 31% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Hyperliquid, a decentralized derivatives exchange, saw its total open interest climb to an all-time high of $11.07 billion on July 13, 2026, according to data from DeFiLlama, cited by Wu Blockchain. The platform’s open interest later settled slightly lower at $10.88 billion, but remained near record levels, indicating robust participation in derivatives trading.
Elevated open interest signals strong activityDeFiLlama, which tracks decentralized finance market metrics, reported that Hyperliquid’s open interest reached its peak for the year as traders kept substantial positions open. Open interest reflects the total value of active derivatives contracts that have yet to be settled or closed out.
Analysts noted that open interest levels above $11 billion indicate strong engagement from market participants, despite minor pullbacks after the spike. Open interest, on its own, does not distinguish between the betting direction of traders; it merely highlights the aggregate capital locked into ongoing contracts.
Open interest gauges not only the activity within derivatives markets but also signals broader leveraged exposure across decentralized finance, irrespective of price direction or momentum.
Market observers continue to compare open interest data with factors like trading volume and price movements to assess risk and leverage in the ecosystem.
HIP-3 and RWA markets drive growthWu Blockchain added that HIP-3 markets contributed approximately $3.69 billion to Hyperliquid’s total open interest, setting a new record for that segment on the decentralized exchange. HIP-3 represents a category of perpetual futures tracking multiple assets, expanding the range of products offered on Hyperliquid.
In addition, MSB Intel reported that real-world asset (RWA) open interest on Hyperliquid surged to about $3.6 billion. This milestone put a spotlight on increased demand for tokenized traditional assets in decentralized trading platforms.
Mini dictionary: RWA (Real-World Assets): Tokenized representations of traditional assets such as commodities, securities, or credit products, traded on blockchain-based platforms.
Institutional interest in tokenized asset derivatives is pushing RWA open interest to new highs, with $3.6 billion reached on Hyperliquid and a total platform open interest of $11 billion for 2026.
The expansion in RWA-based derivatives highlights growing appetite for exposure to non-crypto instruments within decentralized finance. However, analysts emphasize the continued need for effective liquidity monitoring and risk controls as volumes expand.
MarketOpen InterestRecord DateTotal (Hyperliquid)$11.07 billionJuly 13, 2026HIP-3$3.69 billionJuly 13, 2026RWA$3.6 billionJuly 13, 2026Technical levels and future outlookCharts show that Hyperliquid open interest has rebounded sharply from early 2026 lows near $5 billion, forming higher highs and higher lows throughout the year. Analysts point to resistance zones between $11 billion and $12 billion, with a breakout above this level potentially opening the door to targets near $13 billion to $15 billion. The historical peak region between $15 billion and $16 billion also serves as a reference for future movements.
On the downside, initial support lies between $9 billion and $9.5 billion, while a further decline could find stability near $6 billion to $7 billion. These key technical areas may influence trader behavior and leverage deployment across Hyperliquid’s markets.
Hyperliquid’s recent surge in open interest and record-setting performance in both HIP-3 and RWA markets demonstrate the evolving structure and growing sophistication of decentralized derivatives trading in 2026.
Disclaimer: The information contained in this article does not constitute investment advice. Investors should be aware that cryptocurrencies carry high volatility and therefore risk, and should conduct their own research.
Galaxy Digital CEO Mike Novogratz has stated that cryptocurrency volumes have increased by 20% to 30% from previous lows, suggesting a renewed enthusiasm in the market. He highlighted that smaller positive developments are contributing to this upswing. Novogratz’s remarks align with recent data indicating a 19% rise in centralized exchange volumes, a notable growth over four consecutive months. Additionally, Robinhood Chain, an Ethereum Layer 2 network, reported significant usage, surpassing Hyperliquid’s activity on its launch day. This surge in activity on new platforms like Robinhood Chain reflects a shift in liquidity, potentially affecting the dynamics within the crypto market.
Advertisement
Key Takeaways Novogratz’s statement suggests a positive shift in crypto market sentiment, with volumes increasing significantly from recent lows. Robinhood Chain’s debut highlights a migration of liquidity toward emerging networks, surpassing established platforms like Hyperliquid. Market participants appear encouraged by these developments, indicating a shift from speculative interest to practical use cases. What to Watch Observers will be keen to see if the increase in volumes sustains and influences the broader market, particularly in relation to Hyperliquid’s performance. Any further announcements from major platforms like Robinhood or strategic partnerships involving Hyperliquid could provide additional insights. Markets will also watch for shifts in sentiment and volume that could impact the pricing of Hyperliquid, especially as the year progresses toward the end of 2026.
Get live prediction-market analysis, powered by Vera. Sign up for Vera.
Term Structure
Contract Odds Δ since publish Volume 24h December 31 39% — — View market → January 1 2027 5.4% — — View market → January 1 2027 4% — — View market → January 1 2027 68.5% — — View market → January 1 2027 9.2% — — View market → January 1 2027 4.5% — — View market →
Financials Crypto Sector protocols, such as Hyperliquid’s $HYPE, are reportedly outperforming Consumer & Culture Sector tokens. This development is attributed to strong fundamentals, including real cash flows, stablecoins, tokenization, and increased blockchain adoption. Hyperliquid, a decentralized perpetuals exchange, has emerged as a leader in on-chain derivatives, benefiting from fees and a robust token buyback program. The protocol’s success is further bolstered by institutional interest and strategic partnerships, including Circle’s investment and integration with USDC on its HyperEVM platform.
Advertisement
Key Takeaways Market activity suggests that $HYPE’s performance is consistent with a broader trend favoring financial sector tokens with strong cash flow fundamentals. Current pricing indicates a moderate increase in the probability of Hyperliquid reaching $100 by the end of 2026, suggesting positive investor sentiment. The financial sector’s focus on real yield and tokenization appears to be driving market rewards over consumer-focused narratives. What to Watch Watch for further institutional involvement, such as new partnerships or investments, which could support a YES outcome for Hyperliquid reaching $100. Potential risks include regulatory challenges or security breaches that could impact sentiment negatively. Developments in blockchain technology adoption and stablecoin integration will also be key indicators for the protocol’s future performance.
Get live prediction-market analysis, powered by Vera. Sign up for Vera.
Term Structure
Contract Odds Δ since publish Volume 24h December 31 39% — — View market → January 1 2027 5.4% — — View market → January 1 2027 4% — — View market → January 1 2027 68.5% — — View market → January 1 2027 9.2% — — View market → January 1 2027 4.5% — — View market →
Hyperliquid’s HIP-3 markets have experienced a significant increase in perpetual futures market volume, now accounting for nearly 50% of the protocol’s total perp volume. This marks a substantial rise from roughly 2% at the beginning of 2026. The surge is primarily driven by the onchain activity in real-world assets, including tokenized U.S. equities and commodities. With 23 of the top 30 Hyperliquid pairs by open interest, the growth reflects a shift towards 24/7 access to traditional assets, especially during periods of geopolitical volatility when legacy markets are closed. Market participants are increasingly favoring HIP-3’s framework for its ability to offer continuous exposure to these assets.
Advertisement
Key Takeaways The increase in HIP-3’s market share appears consistent with growing interest in onchain access to tokenized real-world assets. Hyperliquid’s recent performance suggests market participants are rotating from altcoins to tokenized stocks and commodities. The rise in onchain stock activity may indicate a longer-term trend toward integrating traditional financial assets into blockchain ecosystems. What to Watch The market will be closely monitoring if Hyperliquid can sustain or further increase its market share in perpetual futures. Key indicators include announcements of partnerships or technological advancements that could enhance Hyperliquid’s offerings. Additionally, developments in geopolitical events or regulatory changes impacting real-world asset tokenization could significantly influence market sentiment and pricing, potentially affecting Hyperliquid’s trajectory towards its $100 price target by the end of 2026.
Get live prediction-market analysis, powered by Vera. Sign up for Vera.
Term Structure
Contract Odds Δ since publish Volume 24h December 31 39% — — View market → January 1 2027 5.4% — — View market → January 1 2027 4% — — View market → January 1 2027 68.5% — — View market → January 1 2027 9.2% — — View market → January 1 2027 4.5% — — View market →
Hyperliquid’s HIP-3 markets have surged to nearly 50% of the protocol’s perpetual futures volume, reflecting a significant shift towards on-chain activity in tokenized traditional assets such as U.S. stocks, commodities, and indices. As of July 12, 2026, the HIP-3 markets have reached an open interest of $3.68 billion, with cumulative volume surpassing $309 billion since the upgrade’s launch in October 2025. This growth underscores the increasing appeal of non-crypto assets in the crypto derivatives markets, as they now dominate seven of Hyperliquid’s top ten volume markets. The trend challenges centralized exchanges and traditional finance infrastructure by attracting more participants towards decentralized avenues.
Advertisement
Key Takeaways The surge in Hyperliquid’s HIP-3 market volume suggests a growing interest in on-chain access to tokenized traditional assets. Non-crypto assets are now predominant in Hyperliquid’s top volume markets, indicating a shift in the focus of crypto derivatives. Market pricing implies that the increased activity could support scenarios where Hyperliquid’s value continues to rise, consistent with increased YES outcomes. What to Watch Future developments could further influence Hyperliquid’s market trajectory. Announcements of major partnerships or technological advancements by Hyperliquid could be supportive of YES scenarios, potentially driving the asset closer to the $100 mark by the end of 2026. Conversely, any reports of security issues or regulatory challenges could suggest scenarios leading to a decline in market confidence. Market participants will be closely monitoring these factors and their potential impacts on Hyperliquid’s pricing trends.
Get live prediction-market analysis, powered by Vera. Sign up for Vera.
Term Structure
Contract Odds Δ since publish Volume 24h December 31 39% — — View market → January 1 2027 5.4% — — View market → January 1 2027 4% — — View market → January 1 2027 68.5% — — View market → January 1 2027 9.2% — — View market → January 1 2027 4.5% — — View market →
Enphase Energy (ENPH - Free Report) closed the most recent trading day at $43.06, moving -3.95% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.79% for the day. Meanwhile, the Dow lost 0.26%, and the Nasdaq, a tech-heavy index, lost 1.55%.
Heading into today, shares of the solar technology company had lost 17.88% over the past month, lagging the Oils-Energy sector's loss of 3.33% and the S&P 500's gain of 4.28%.
Investors will be eagerly watching for the performance of Enphase Energy in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on July 28, 2026. In that report, analysts expect Enphase Energy to post earnings of $0.46 per share. This would mark a year-over-year decline of 33.33%. Meanwhile, our latest consensus estimate is calling for revenue of $292.17 million, down 19.55% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of $2.1 per share and revenue of $1.22 billion, which would represent changes of -29.05% and -16.99%, respectively, from the prior year.
Any recent changes to analyst estimates for Enphase Energy should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 1.2% decrease. Enphase Energy currently has a Zacks Rank of #3 (Hold).
Looking at valuation, Enphase Energy is presently trading at a Forward P/E ratio of 21.37. This signifies no noticeable deviation in comparison to the average Forward P/E of 21.37 for its industry.
The Solar industry is part of the Oils-Energy sector. This industry currently has a Zacks Industry Rank of 59, which puts it in the top 24% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
The Pump.fun business model is making profits at a much quicker pace than it is spending on narratives. According to the recent data, the platform’s annualized revenue has hit $344 million, with the network earning approximately $944,000 every day for the past three months.
Meanwhile, more than $407 million worth of PUMP tokens have already been bought back and removed from circulation.
In simple terms, PUMP is no longer relying solely on speculation. The platform is generating enough cash flow to consistently return value to token holders.
Source: Pump.fun Approximately half of the revenue is returning According to AMBCrypto’s close analysis on the network data, over 50% of its revenue is allocated to token buybacks. This cements the network’s long-term project of reducing circulating supply while at the same time boosting its volatility.
Every day when the platform generates income, some part of the income is spent on buying PUMP coins from the market before destroying them.
The impact of the process has been significant. Up until now, 149 billion PUMP tokens have been destroyed, thereby covering almost 15 percent of the entire circulating supply.
The process does not guarantee higher prices. However, it creates a steady source of demand regardless of broader market conditions.
Source: Pump.fun How are network users reacting to the developments? Normally, buybacks are only effective if the underlying business continues generating revenue. At least for now, that does not seem to be the case.
The number of active addresses is still high. In most cases, it has exceeded 7,000 users per day throughout the past few months. The consistency matters since it suggests that the platform’s revenue is being supported by actual network activity rather than a short-lived spike in trading volume.
In other words, the allocation of a bigger proportion of revenue on buyback seems to bear some fruit. If the activity sustains, the current bullish momentum could be accelerated.
Source: Santiment Is $0.001698 next for PUMP? On the daily chart, the token’s price action has just broken past the 20-period Simple Moving Average (20 SMA). The Bollinger Band’s divergence is wide enough, suggesting that the market still has more volatility for a potential explosive move. But the direction is not clear.
However, with the token Stochastic RSI now dropping below 25, which often points to an oversold market, the current bullish push could be prolonged. At press time the token had recorded a 10% surge and was trading at around $0.001495.
The resistance level at $0.001698 stands as the next target for the market buyer if the current bullish run is sustained.
All in all, Pump.fun is already generating nearly $1 million per day. If that pace continues, buybacks will continue removing supply regardless of short-term market sentiment. When combined with positive technicals, the projected bullish run continuation nears certainty.
Source: TradingView Final Summary Pump.fun’s annualized revenue has surged to $344 million, with the platform generating nearly $944,000 per day over the past three months. More than $407 million has been allocated to buybacks, removing nearly 15% of PUMP’s total supply from circulation.
EWING, N.J.--(BUSINESS WIRE)--Universal Display Corporation (Nasdaq: OLED), a global leader in energy-efficient OLED technologies and materials, today announced its results for the second quarter, ended June 30, 2026, will be released on Thursday, July 30, 2026, after market close. At that time, a copy of the financial results release will be available on the Company’s website at https://oled.com/.
In conjunction with this release, Universal Display will host a conference call on Thursday, July 30, 2026, at 5:00 p.m. Eastern Time. The live webcast of the conference call can be accessed under the events page of the Company's Investor Relations website at ir.oled.com. Those wishing to participate in the live call should dial 1-877-524-8416 (toll-free) or 1-412-902-1028. Please dial in 5-10 minutes prior to the scheduled conference call time. An online archive of the webcast will be available within two hours of the conclusion of the call.
About Universal Display Corporation
Universal Display Corporation (Nasdaq: OLED) is a leader in the research, development and commercialization of organic light emitting diode (OLED) technologies and materials for use in display and solid-state lighting applications. Founded in 1994 and with subsidiaries and offices around the world, the Company currently owns, exclusively licenses or has the sole right to sublicense more than 6,500 patents issued and pending worldwide. Universal Display licenses its proprietary technologies, including its breakthrough high-efficiency UniversalPHOLED® phosphorescent OLED technology that can enable the development of energy-efficient and eco-friendly displays and solid-state lighting. The Company also develops and offers high-quality, state-of-the-art UniversalPHOLED materials that are recognized as key ingredients in the fabrication of OLEDs with peak performance. In addition, Universal Display delivers innovative and customized solutions to its clients and partners through technology transfer, collaborative technology development and on-site training. To learn more about Universal Display Corporation, please visit https://oled.com/.
Universal Display Corporation and the Universal Display Corporation logo are trademarks or registered trademarks of Universal Display Corporation. All other Company, brand or product names may be trademarks or registered trademarks.
All statements in this document that are not historical, such as those relating to the projected adoption, development and advancement of the Company’s technologies, and the Company’s expected results and future declaration of dividends, as well as the growth of the OLED market and the Company’s opportunities in that market, are forward-looking financial statements within the meaning of the Private Securities Litigation Reform Act of 1995. You are cautioned not to place undue reliance on any forward-looking statements in this document, as they reflect Universal Display Corporation’s current views with respect to future events and are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated. These risks and uncertainties are discussed in greater detail in Universal Display Corporation’s periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission, including, in particular, the section entitled “Risk Factors” in Universal Display Corporation’s Annual Report on Form 10-K for the year ended December 31, 2025. Universal Display Corporation disclaims any obligation to update any forward-looking statement contained in this document.
Follow Universal Display Corporation
X
LinkedIn
Facebook
YouTube
The U.S. government has transferred 2,874.9 Bitcoin worth approximately $183.28 million to Coinbase Prime, according to blockchain data shared by Galaxy Research.
The transaction was performed across Bitcoin blocks 957893 and 957894 from a government-controlled address.
The latest movement brings the total amount of BTC sent by U.S. authorities to Coinbase Prime today to nearly 4,000 BTC.
HOT Stories
Speculation about transfer The translation has raised some speculation about whether the coins could be prepared for liquidation or internal custody operations.
In March 2025, an executive order was signed to establish the Strategic Bitcoin Reserve, directing the Treasury Department.
Treasury Secretary Scott Bessent previously said that the government would not purchase Bitcoin directly for the Strategic Bitcoin Reserve but would retain confiscated BTC instead of selling it.
You Might Also Like
The latest Coinbase Prime transfer has therefore raised questions among investors about whether the US government is preparing for potential sales.
imagine US gov is selling
— RunnerMU (Micron-san) (@RunnerXBT) July 13, 2026 Notably, the coins trace to multiple unrelated cases (BTC-e and others). It is highly unusual for the government to move them at the same time.
The Bitcoin treasury firm Strategy (MSTR) has now gone three consecutive weeks without buying any BTC.
On Monday, Strategy Chairman Michael Saylor announced the company increased its US dollar reserve by $450 million over the past week but opted not to buy any new Bitcoin.
Over the two weeks prior, the firm sold a total of 3,588 BTC for $216 million. The sales, which sparked headlines across the crypto sector, materialized under the Strategy’s newly introduced BTC monetization program, designed to bolster the firm’s cash reserve and support dividend payments.
The firm still holds 843,775 Bitcoin worth $52.47 billion at time of writing, as well as $3 billion in cash reserves.
In May, Strategy sold 32 BTC worth $2.47 million, the company’s first Bitcoin sale since 2022, when the firm’s subsidiary, MacroStrategy, hawked 704 BTC for approximately $11.8 million.
The May sale marked a dramatic shift in tone for Strategy after Saylor spent years encouraging investors to “never sell” their BTC.
He did tip that a sale could happen, however, suggesting in a first-quarter earnings call that the firm would “probably sell some Bitcoin to fund a dividend just to inoculate the market – just to send the message that we did it.”
Strategy was the first public company to adopt Bitcoin as its sole treasury reserve asset and remains the world’s largest corporate holder of BTC by a wide margin.
Bitcoin has entered a high-risk week as fresh inflation data and renewed Federal Reserve rate concerns have intensified pressure on crypto markets.
Summary
Bitcoin faces renewed pressure ahead of the U.S. CPI and PPI inflation reports. Fed Governor Christopher Waller’s hawkish comments have lifted September rate hike expectations. Investors are also tracking CLARITY Act developments as another key crypto market catalyst. According to Reuters, Federal Reserve Governor Christopher Waller warned that the U.S. central bank could consider raising interest rates if inflation continues to remain above its 2% target, placing investors on alert before this week’s key economic releases.
His comments come as traders prepare for the June Consumer Price Index (CPI) report due on July 14, followed by the Producer Price Index (PPI) data on July 15.
Bitcoin has already reacted to rising macro uncertainty. The cryptocurrency slipped below $62,000 after climbing to around $64,500 earlier, with escalating tensions between the United States and Iran adding another layer of risk to global financial markets.
Higher geopolitical uncertainty has combined with growing expectations of tighter monetary policy to weaken demand for risk assets.
Inflation data could shape Fed expectations Wall Street economists expect the June CPI report to show monthly inflation easing to 0.2% from 0.5% in May. Annual inflation is projected to slow to 3.8% from 4.2%, offering investors another measure of whether price pressures are cooling.
The inflation figures are likely to influence expectations for future Federal Reserve policy. If consumer prices rise faster than forecast, markets could strengthen their bets that policymakers may keep interest rates higher for longer or even consider another increase.
Attention will then turn to the June PPI report, which measures inflation at the wholesale level. Together, the two reports are expected to provide a clearer picture of inflation trends across the U.S. economy and could influence trading across equities, bonds and digital assets.
Following Waller’s remarks, the CME FedWatch Tool showed that the probability of a September Federal Reserve rate hike climbed to 51.3%. Higher borrowing costs typically reduce appetite for speculative investments, making cryptocurrencies particularly sensitive to changes in monetary policy expectations.
Source: FedWatch Recent Federal Reserve communications have already pointed to persistent inflation risks. Minutes from the central bank’s latest policy meeting noted that several officials remain concerned about inflationary pressures, including those linked to rising artificial intelligence investment and stronger-than-expected economic activity, keeping markets cautious ahead of this week’s data releases.
Crypto legislation adds another market catalyst While inflation remains the primary focus, investors are also monitoring developments in Washington as lawmakers prepare for another important week for the CLARITY Act, one of the most closely watched crypto market structure bills.
U.S. President Donald Trump recently urged the Senate to pass the legislation in honor of Senator Lindsey Graham, who died on July 11. The bill is expected to receive renewed attention this week as lawmakers continue discussions over its final form.
The legislation seeks to establish a clearer regulatory framework for digital assets in the United States. Market participants have been watching the proposal closely because it could determine how cryptocurrencies are regulated by federal agencies and influence future institutional participation in the sector.
With inflation reports, Federal Reserve policy expectations, geopolitical tensions, and crypto legislation all converging within days, investors are preparing for another volatile trading week.
Softer-than-expected inflation could ease pressure on risk assets, while stronger readings may reinforce expectations for tighter monetary policy and keep cryptocurrencies under pressure.
Bitcoin (CRYPTO: BTC) may be entering the final stages of its bear market as higher-timeframe technical indicators increasingly point towards a long-term bottom.
Multiple Bullish SignalsIn a "Kev Capital" podcast on July 13, crypto analyst Kevin said he is not attempting to pinpoint the exact bottom but instead is gradually building exposure based on improving technical conditions.
He added that BTC is now showing multiple bullish signals on higher timeframes, including the weekly and two-week charts, rather than just shorter-term indicators.
Among the signals he highlighted are technical bullish divergences and BTC trading near its 12-day 200 EMA and 200 SMA—areas that have historically coincided with major cycle lows.
Kevin says he believes Bitcoin could still revisit the $44,000 to $56,000 region before a durable bottom is established but stressed that such a move would not alter his accumulation strategy.
The analyst argued that disciplined dollar-cost averaging has historically been a more effective strategy than waiting for a single-entry price.
Kevin also cited stablecoin dominance as another indicator supporting his bullish medium-term outlook.
Those signals suggest selling pressure is fading and that “the Bitcoin bears are finally getting weaker.”
Image: Shutterstock
Market News and Data brought to you by Benzinga APIs
Bitcoin prices dropped as geopolitical concerns fueled losses.
getty
Bitcoin prices took a tumble on Monday, July 13, falling as global markets responded to the latest geopolitical tensions involving the Straight of Hormuz.
This development combined with other factors to place downward pressure on the digital asset’s price.
The world’s most valuable digital currency dropped to $61,750.90, according to Coinbase data from TradingView. At this point, the cryptocurrency was down roughly 4% after rising to nearly $64,400 earlier in the day.
Major stock indices including the S&P 500 and the Dow Jones Industrial Average also pushed lower during the day, according to Google Finance data.
“Bitcoin’s recent weakness has been driven by a broader risk-off move across global markets,” Roy Kashi, co-founder and CEO of Falconedge, stated via email.
“Rising tensions between the U.S. and Iran have pushed oil prices higher, reignited inflation concerns and reduced expectations for near-term rate cuts, prompting investors to trim exposure to risk assets.”
MORE FOR YOU
Tal Fromchenko, Founder and CEO of Leveraged, offered a similar take, while also citing additional causal factors.
“The pullback to $62,000 is primarily driven by escalating U.S.-Iran tensions over the Strait of Hormuz, which sparked a broader shift away from risk assets while cooling institutional ETF inflows and triggering leveraged long liquidations after Bitcoin failed to break past key resistance on Friday,” he said through emailed comments.
“However, this remains a standard macro-driven flush within a historically healthy multi-year market cycle, leaving Bitcoin’s broader structural trajectory for growth entirely intact,” added Fromchenko, who provided a bullish outlook.
Himanshu Sahay, cofounder and CTO of crypto lender Arch, also weighed in, pointing to various factors when explaining bitcoin’s latest price movements.
“I don’t think this decline is the result of any one event. It’s more likely the market reacting to a mix of macro sentiment, positioning and liquidity, all of which can change pretty quickly,” he noted through emailed commentary.
Saeed Al-Marri, CEO at Ethra Invest, took a different tack, choosing to focus on market factors and an upcoming inflation report due for release later this week.
“I think on the technical side what we’re seeing looks like a wave of liquidations, not a loss of faith in Bitcoin. When traders go long, essentially borrowing money to bet the price will rise, then any drop basically forces exchanges to automatically liquidate those positions once losses hit a limit,” he stated via email.
“Right now, longs are being liquidated six times as often as shorts (6 to 1), which tells you this is bullish bets getting wiped out, not a broad exit from the asset.”
“And on the macro side the bigger driver is what’s coming on Wednesday: US Consumer Price Index (inflation data),” he continued. "If it comes in hot, it pushes back any hope of the Fed cutting interest rates soon, and higher rates make safer options like bonds and cash more attractive than a volatile asset like Bitcoin.
“That’s the real story right now. Its not Bitcoin breaking down, but the whole market waiting on a single number from the CPI.”
Bitcoin prices dropped as geopolitical concerns fueled losses.
getty
Bitcoin prices took a tumble on Monday, July 13, falling as global markets responded to the latest geopolitical tensions involving the Straight of Hormuz.
This development combined with other factors to place downward pressure on the digital asset’s price.
The world’s most valuable digital currency dropped to $61,750.90, according to Coinbase data from TradingView. At this point, the cryptocurrency was down roughly 4% after rising to nearly $64,400 earlier in the day.
Major stock indices including the S&P 500 and the Dow Jones Industrial Average also pushed lower during the day, according to Google Finance data.
“Bitcoin’s recent weakness has been driven by a broader risk-off move across global markets,” Roy Kashi, co-founder and CEO of Falconedge, stated via email.
“Rising tensions between the U.S. and Iran have pushed oil prices higher, reignited inflation concerns and reduced expectations for near-term rate cuts, prompting investors to trim exposure to risk assets.”
MORE FOR YOU
Tal Fromchenko, Founder and CEO of Leveraged, offered a similar take, while also citing additional causal factors.
“The pullback to $62,000 is primarily driven by escalating U.S.-Iran tensions over the Strait of Hormuz, which sparked a broader shift away from risk assets while cooling institutional ETF inflows and triggering leveraged long liquidations after Bitcoin failed to break past key resistance on Friday,” he said through emailed comments.
“However, this remains a standard macro-driven flush within a historically healthy multi-year market cycle, leaving Bitcoin’s broader structural trajectory for growth entirely intact,” added Fromchenko, who provided a bullish outlook.
Himanshu Sahay, cofounder and CTO of crypto lender Arch, also weighed in, pointing to various factors when explaining bitcoin’s latest price movements.
“I don’t think this decline is the result of any one event. It’s more likely the market reacting to a mix of macro sentiment, positioning and liquidity, all of which can change pretty quickly,” he noted through emailed commentary.
Saeed Al-Marri, CEO at Ethra Invest, took a different tack, choosing to focus on market factors and an upcoming inflation report due for release later this week.
“I think on the technical side what we’re seeing looks like a wave of liquidations, not a loss of faith in Bitcoin. When traders go long, essentially borrowing money to bet the price will rise, then any drop basically forces exchanges to automatically liquidate those positions once losses hit a limit,” he stated via email.
“Right now, longs are being liquidated six times as often as shorts (6 to 1), which tells you this is bullish bets getting wiped out, not a broad exit from the asset.”
“And on the macro side the bigger driver is what’s coming on Wednesday: US Consumer Price Index (inflation data),” he continued. "If it comes in hot, it pushes back any hope of the Fed cutting interest rates soon, and higher rates make safer options like bonds and cash more attractive than a volatile asset like Bitcoin.
“That’s the real story right now. Its not Bitcoin breaking down, but the whole market waiting on a single number from the CPI.”
In brief New Hampshire's governor signed the Blockchain Basics Law, introducing new protections for blockchain innovation and crypto users in the state. Last year, the state became the first in the nation to introduce a strategic Bitcoin reserve, allowing for up to 5% of public funds to be invested in the leading crypto asset. However, its executive council recently rejected the allowance of the first Bitcoin-backed municipal bond. New Hampshire Governor Kelly Ayotte helped make the state into one of the crypto-friendliest in the nation when she signed HB 639 into law last week.
Known as the The Blockchain Basic Laws act, the bill provides protections for cryptocurrency innovation and use in the state while also allowing for the creation of a special blockchain dispute docket in the superior court.
"With Governor Ayotte's signature on HB 639, New Hampshire has once again demonstrated that it intends to lead the nation in blockchain innovation," said New Hampshire Representative Keith Ammon, the bill’s primary sponsor, in a statement.
“The Blockchain Basic Laws protect one of the most fundamental rights in the digital economy—the right of individuals to control their own digital assets through self-custody,” he added. “They also provide clear legal protections for blockchain developers, miners, validators, entrepreneurs, and businesses building the next generation of financial technology.”
The state’s latest blockchain legislation follows its passing of a strategic Bitcoin reserve last year. The bill, signed by Ayotte in May 2025, allows the state’s treasurer to invest up to 5% of its public funds in the leading crypto asset, alongside precious metals like gold and silver.
Ammon, who played a key role in that bill’s passage, told Decrypt at the time it was “one little way our state could hedge against inflation in the future."
“Today, with the signing of HB 639, we have taken another major step by enacting one of the most comprehensive blockchain rights laws in the country,” he said in a statement. “Entrepreneurs, investors, developers, and innovators across America should know that New Hampshire is open for blockchain business."
Despite its advances, the state’s executive council last week blocked a proposal that would have allowed the New Hampshire Business Finance Authority to facilitate a Bitcoin-backed municipal bond.
Daily Debrief NewsletterStart every day with the top news stories right now, plus original features, a podcast, videos and more.
